Jump to section

References

Trials

Economics

Properties

Spectra

Taxonomy

Venlafaxine

Targets (3)Enzymes (5)Transporters (2)Biointeractions (13)

Identification

Name

Venlafaxine

Accession Number

DB00285 (APRD00125)

Type

Small Molecule

Groups

Approved

Description

Venlafaxine (Effexor) is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class first introduced by Wyeth in 1993. It is prescribed for the treatment of clinical depression and anxiety disorders. Due to the pronounced side effects and suspicions that venlafaxine may significantly increase the risk of suicide it is not recommended as a first line treatment of depression. However, it is often effective for depression not responding to SSRIs. Venlafaxine was the sixth most widely-used antidepressant based on the amount of retail prescriptions in the US (17.1 million) in 2006. [Wikipedia]

Structure

Similar Structures

Synonyms

Elafax
Venlafaxina
Venlafaxine
Venlafaxinum

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Venlafaxine Hydrochloride	7D7RX5A8MO	99300-78-4	QYRYFNHXARDNFZ-UHFFFAOYNA-N

Product Images

Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Act Venlafaxine XR	Capsule, extended release	150.0 mg	Oral	Actavis Pharma Company	2008-02-13	Not applicable
Act Venlafaxine XR	Capsule, extended release	37.5 mg	Oral	Actavis Pharma Company	2008-02-13	Not applicable
Act Venlafaxine XR	Capsule, extended release	75.0 mg	Oral	Actavis Pharma Company	2008-02-13	Not applicable
Auro-venlafaxine XR	Capsule, extended release	150 mg	Oral	Auro Pharma Inc	2016-03-14	Not applicable
Auro-venlafaxine XR	Capsule, extended release	37.5 mg	Oral	Auro Pharma Inc	2016-03-14	Not applicable
Auro-venlafaxine XR	Capsule, extended release	75 mg	Oral	Auro Pharma Inc	2016-03-14	Not applicable
Dom-venlafaxine XR	Capsule, extended release	150 mg	Oral	Dominion Pharmacal	2013-05-30	Not applicable
Dom-venlafaxine XR	Capsule, extended release	37.5 mg	Oral	Dominion Pharmacal	2013-05-23	Not applicable
Dom-venlafaxine XR	Capsule, extended release	75 mg	Oral	Dominion Pharmacal	2013-05-23	Not applicable
Effexor Tablets, 37.5mg	Tablet	37.5 mg	Oral	Wyeth Ltd.	1994-12-31	2004-08-19

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Apo-venlafaxine XR	Capsule, extended release	37.5 mg	Oral	Apotex Corporation	2013-04-16	Not applicable
Apo-venlafaxine XR	Capsule, extended release	75 mg	Oral	Apotex Corporation	2013-04-16	Not applicable
Apo-venlafaxine XR	Capsule, extended release	150 mg	Oral	Apotex Corporation	2013-04-16	Not applicable
Effexor	Tablet	50 mg/1	Oral	Directrx	2016-02-02	Not applicable
Venlafaxine	Tablet	37.5 mg/1	Oral	North Star Rx Llc	2010-12-21	Not applicable
Venlafaxine	Tablet	50 mg/1	Oral	Qualitest	2010-08-04	2016-10-13
Venlafaxine	Tablet	50 mg/1	Oral	Alembic Pharmaceuticals Limited	2015-10-01	Not applicable
Venlafaxine	Tablet	37.5 mg/1	Oral	Remedy Repack	2013-05-29	2017-03-02
Venlafaxine	Tablet	25 mg/1	Oral	Heritage	2012-11-30	Not applicable
Venlafaxine	Tablet	50 mg/1	Oral	Sun Pharmaceutical Industries Limited	2008-06-13	Not applicable

International/Other Brands

Effexor / Elafax

Categories

UNII

GRZ5RCB1QG

CAS number

93413-69-5

Weight

Average: 277.4018
Monoisotopic: 277.204179113

Chemical Formula

C₁₇H₂₇NO₂

InChI Key

PNVNVHUZROJLTJ-UHFFFAOYSA-N

InChI

InChI=1S/C17H27NO2/c1-18(2)13-16(17(19)11-5-4-6-12-17)14-7-9-15(20-3)10-8-14/h7-10,16,19H,4-6,11-13H2,1-3H3

IUPAC Name

1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol

SMILES

COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1

Pharmacology

Indication

For the management of major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder (social phobia), panic disorder with or without agoraphobia, vasomotor symptoms in women with breast cancer and in postmenopausal women, and neuropathic pain.

Structured Indications

Pharmacodynamics

Venlafaxine potentiates the neurotransmitter activity in the central nervous system. Furthermore, venlafaxine and its metabolite, O-desmethylvenlafaxine (ODV) potently inhibit the reuptake of serotonin and norepinephrine and weakly inhibit dopamine reuptake. Both molecules do not bind to muscarinic, histaminergic, or alpha-1 adrenergic receptors. Pharmacologic activity at these receptors is hypothesized to be associated with the various anticholinergic, sedative, and cardiovascular effects seen with other psychotropic drugs. Both also do not have any monoamine oxidase (MAO) inhibitory activity.

Mechanism of action

The exact mechanism of action of venlafaxine is unknown, but appears to be associated with the its potentiation of neurotransmitter activity in the CNS. Venlafaxine and its active metabolite, O-desmethylvenlafaxine (ODV), inhibit the reuptake of both serotonin and norepinephrine with a potency greater for the 5-HT than for the NE reuptake process. Both venlafaxine and the ODV metabolite have weak inhibitory effects on the reuptake of dopamine but, unlike the tricyclics and similar to SSRIs, they are not active at histaminergic, muscarinic, or alpha(1)-adrenergic receptors.

Target	Actions	Organism
ASodium-dependent serotonin transporter	inhibitor	Human
ASodium-dependent noradrenaline transporter	inhibitor	Human
USodium-dependent dopamine transporter	inhibitor	Human

Absorption

Venlafaxine is well absorbed. Food does not effect the absorption of venlafaxine or its subsequent metabolism into ODV. Bioavailability is 45% following oral administration. Time to steady state = 3 days.

Volume of distribution

7.5 ± 3.7 L/kg [venlafaxine]
5.7 ± 1.8 L/kg [O-desmethylvenlafaxine(active metabolite)]

Protein binding

The degree of binding of venlafaxine to human plasma is 27% ± 2% at concentrations ranging from 2.5 to 2215 ng/mL. The degree of ODV binding to human plasma is 30% ± 12% at concentrations ranging from 100 to 500 ng/mL. Protein-binding-induced drug interactions with venlafaxine are not expected.

Metabolism

Undergoes extensive first pass metabolism in the liver to its major, active metabolite, ODV, and two minor, less active metabolites, N-desmethylvenlafaxine and N,O-didesmethylvenlafaxine. Formation of ODV is catalyzed by cytochrome P450 (CYP) 2D6, whereas N-demethylation is catalyzed by CYP3A4, 2C19 and 2C9. ODV possesses antidepressant activity that is comparable to that of venlfaxine.

Reactions:

Route of elimination

Renal elimination of venlafaxine and its metabolites is the primary route of excretion. Approximately 87% of a venlafaxine dose is recovered in the urine within 48 hours as either unchanged venlafaxine (5%), unconjugated ODV (29%), conjugated ODV (26%), or other minor inactive metabolites (27%).

Half life

5 hours

Clearance

Steady state plasma clearance, venlafaxine = 1.3 ± 0.6 L/h/kg; Steady state plasma clearance, ODV = 0.4 ± 0.2 L/h/kg.

Toxicity

Most patients overdosing with venlafaxine develop only mild symptoms. However, severe toxicity is reported with the most common symptoms being CNS depression, serotonin toxicity, seizure, or cardiac conduction abnormalities. Venlafaxine's toxicity appears to be higher than other SSRIs, with a fatal toxic dose closer to that of the tricyclic antidepressants than the SSRIs. Doses of 900 mg or more are likely to cause moderate toxicity. Deaths have been reported following large doses.

Affected organisms

Humans and other mammals

Pathways

Pathway	Category
Venlafaxine Metabolism Pathway	Drug metabolism

Pharmacogenomic Effects/ADRs

Interacting Gene/Enzyme	Allele name	Genotype(s)	Defining Change(s)	Type(s)	Description	Details
Cytochrome P450 2D6	CYP2D6*4	(A;A) / (A;A)	A Allele / A Allele	Effect Directly Studied	Patients with this genotype have reduced metabolism of venlafaxine.	Details
Cytochrome P450 2D6	CYP2D6*6	(-;-) / (-;T) / (-;-)	T deletion / T deletion, homozygote	Effect Directly Studied	Patients with this genotype have reduced metabolism of venlafaxine.	Details
Cytochrome P450 2D6	CYP2D6*5	Not Available	Whole gene deletion, homozygote	Effect Directly Studied	Patients with this genotype have reduced metabolism of venlafaxine.	Details
Multidrug resistance protein 1	---	(C;C) / (C;T)	C Allele	Effect Directly Studied	Patients with this genotype have an increased likelihood of remission when using venlafaxine to treat major depressive disorder	Details
Multidrug resistance protein 1	---	(C;C) / (C;T)	T > C	Effect Directly Studied	Patients with this genotype have increased risk of adverse events with venlafaxine	Details
Cytochrome P450 2D6	CYP2D6*3	Not Available	C allele	Effect Inferred	Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea	Details
Cytochrome P450 2D6	CYP2D6*7	Not Available	2935A>C	Effect Inferred	Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea	Details
Cytochrome P450 2D6	CYP2D6*8	Not Available	1758G>T	Effect Inferred	Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea	Details
Cytochrome P450 2D6	CYP2D6*11	Not Available	883G>C	Effect Inferred	Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea	Details
Cytochrome P450 2D6	CYP2D6*12	Not Available	124G>A	Effect Inferred	Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea	Details
Cytochrome P450 2D6	CYP2D6*13	Not Available	CYP2D7/2D6 hybrid gene structure	Effect Inferred	Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea	Details
Cytochrome P450 2D6	CYP2D6*14A	Not Available	1758G>A	Effect Inferred	Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea	Details
Cytochrome P450 2D6	CYP2D6*15	Not Available	137insT, 137_138insT	Effect Inferred	Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea	Details
Cytochrome P450 2D6	CYP2D6*19	Not Available	2539_2542delAACT	Effect Inferred	Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea	Details
Cytochrome P450 2D6	CYP2D6*20	Not Available	1973_1974insG	Effect Inferred	Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea	Details
Cytochrome P450 2D6	CYP2D6*21	Not Available	2573insC	Effect Inferred	Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea	Details
Cytochrome P450 2D6	CYP2D6*31	Not Available	-1770G>A / -1584C>G … show all	Effect Inferred	Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea	Details
Cytochrome P450 2D6	CYP2D6*36	Not Available	100C>T / -1426C>T … show all	Effect Inferred	Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea	Details
Cytochrome P450 2D6	CYP2D6*38	Not Available	2587_2590delGACT	Effect Inferred	Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea	Details
Cytochrome P450 2D6	CYP2D6*40	Not Available	1863_1864ins(TTT CGC CCC)2	Effect Inferred	Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea	Details
Cytochrome P450 2D6	CYP2D6*42	Not Available	3259_3260insGT	Effect Inferred	Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea	Details
Cytochrome P450 2D6	CYP2D6*44	Not Available	2950G>C	Effect Inferred	Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea	Details
Cytochrome P450 2D6	CYP2D6*47	Not Available	100C>T / -1426C>T … show all	Effect Inferred	Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea	Details
Cytochrome P450 2D6	CYP2D6*51	Not Available	-1584C>G / -1235A>G … show all	Effect Inferred	Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea	Details
Cytochrome P450 2D6	CYP2D6*56	Not Available	3201C>T	Effect Inferred	Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea	Details
Cytochrome P450 2D6	CYP2D6*57	Not Available	100C>T / 310G>T … show all	Effect Inferred	Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea	Details
Cytochrome P450 2D6	CYP2D6*62	Not Available	4044C>T	Effect Inferred	Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea	Details
Cytochrome P450 2D6	CYP2D6*68A	Not Available	-1426C>T / -1235A>G … show all	Effect Inferred	Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea	Details
Cytochrome P450 2D6	CYP2D6*68B	Not Available	Similar but not identical switch region compared to CYP2D668A. Found in tandem arrangement with CYP2D64.	Effect Inferred	Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea	Details
Cytochrome P450 2D6	CYP2D6*69	Not Available	2988G>A / -1426C>T … show all	Effect Inferred	Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea	Details
Cytochrome P450 2D6	CYP2D6*92	Not Available	1995delC	Effect Inferred	Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea	Details
Cytochrome P450 2D6	CYP2D6*100	Not Available	-1426C>T / -1235A>G … show all	Effect Inferred	Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea	Details
Cytochrome P450 2D6	CYP2D6*101	Not Available	-1426C>T / -1235A>G … show all	Effect Inferred	Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea	Details

Interactions

Drug Interactions

Drug	Interaction	Drug group
4-Methoxyamphetamine	The metabolism of 4-Methoxyamphetamine can be decreased when combined with Venlafaxine.	Experimental, Illicit
7-Nitroindazole	The risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Venlafaxine.	Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline	7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Venlafaxine.	Experimental
Abiraterone	The serum concentration of Venlafaxine can be increased when it is combined with Abiraterone.	Approved
Acarbose	Venlafaxine may increase the hypoglycemic activities of Acarbose.	Approved, Investigational
Acebutolol	The serum concentration of Acebutolol can be increased when it is combined with Venlafaxine.	Approved
Acenocoumarol	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Acenocoumarol.	Approved
Acepromazine	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Acepromazine.	Approved, Vet Approved
Aceprometazine	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Aceprometazine.	Approved
Acetaminophen	The metabolism of Acetaminophen can be decreased when combined with Venlafaxine.	Approved
Acetophenazine	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Acetophenazine.	Approved
Acetylcholine	The metabolism of Acetylcholine can be decreased when combined with Venlafaxine.	Approved
Acetylsalicylic acid	Venlafaxine may increase the antiplatelet activities of Acetylsalicylic acid.	Approved, Vet Approved
Adinazolam	The metabolism of Adinazolam can be decreased when combined with Venlafaxine.	Approved
Adipiplon	The risk or severity of adverse effects can be increased when Adipiplon is combined with Venlafaxine.	Investigational
Adrafinil	Venlafaxine may increase the tachycardic activities of Adrafinil.	Withdrawn
Afatinib	The serum concentration of Afatinib can be increased when it is combined with Venlafaxine.	Approved
Agmatine	Venlafaxine may decrease the antihypertensive activities of Agmatine.	Experimental, Investigational
Agomelatine	The risk or severity of adverse effects can be increased when Agomelatine is combined with Venlafaxine.	Approved, Investigational
Ajmaline	The metabolism of Ajmaline can be decreased when combined with Venlafaxine.	Approved
Alaproclate	Venlafaxine may increase the serotonergic activities of Alaproclate.	Experimental
Albendazole	The metabolism of Albendazole can be decreased when combined with Venlafaxine.	Approved, Vet Approved
Albiglutide	Venlafaxine may increase the hypoglycemic activities of Albiglutide.	Approved
Alclometasone	The metabolism of Alclometasone can be decreased when combined with Venlafaxine.	Approved
Aldosterone	The serum concentration of Venlafaxine can be decreased when it is combined with Aldosterone.	Experimental
Alectinib	The serum concentration of Venlafaxine can be increased when it is combined with Alectinib.	Approved
Alfaxalone	The risk or severity of adverse effects can be increased when Alfaxalone is combined with Venlafaxine.	Vet Approved
Alfentanil	The metabolism of Alfentanil can be decreased when combined with Venlafaxine.	Approved, Illicit
Alfuzosin	The metabolism of Alfuzosin can be decreased when combined with Venlafaxine.	Approved, Investigational
Aliskiren	The metabolism of Aliskiren can be decreased when combined with Venlafaxine.	Approved, Investigational
Alitretinoin	The serum concentration of Alitretinoin can be increased when it is combined with Venlafaxine.	Approved, Investigational
Allopregnanolone	The risk or severity of adverse effects can be increased when Allopregnanolone is combined with Venlafaxine.	Investigational
Allylestrenol	The metabolism of Allylestrenol can be decreased when combined with Venlafaxine.	Approved
Almotriptan	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Almotriptan.	Approved, Investigational
Alogliptin	The metabolism of Alogliptin can be decreased when combined with Venlafaxine.	Approved
Alosetron	The metabolism of Alosetron can be decreased when combined with Venlafaxine.	Approved, Withdrawn
Alphacetylmethadol	Alphacetylmethadol may increase the serotonergic activities of Venlafaxine.	Experimental, Illicit
Alphaprodine	Alphaprodine may increase the serotonergic activities of Venlafaxine.	Illicit
Alprazolam	The metabolism of Alprazolam can be decreased when combined with Venlafaxine.	Approved, Illicit, Investigational
Alprenolol	The metabolism of Alprenolol can be decreased when combined with Venlafaxine.	Approved, Withdrawn
Amantadine	The serum concentration of Venlafaxine can be increased when it is combined with Amantadine.	Approved
Ambrisentan	The metabolism of Ambrisentan can be decreased when combined with Venlafaxine.	Approved, Investigational
Ambroxol	The metabolism of Ambroxol can be decreased when combined with Venlafaxine.	Approved
Amibegron	Venlafaxine may increase the tachycardic activities of Amibegron.	Investigational
Aminohippuric acid	The serum concentration of Venlafaxine can be increased when it is combined with Aminohippuric acid.	Approved
Aminophenazone	The metabolism of Aminophenazone can be decreased when combined with Venlafaxine.	Approved, Withdrawn
Aminophylline	The metabolism of Aminophylline can be decreased when combined with Venlafaxine.	Approved
Amiodarone	The metabolism of Venlafaxine can be decreased when combined with Amiodarone.	Approved, Investigational
Amisulpride	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Amisulpride.	Approved, Investigational
Amitraz	Venlafaxine may increase the tachycardic activities of Amitraz.	Vet Approved
Amitriptyline	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Amitriptyline.	Approved
Amlodipine	The metabolism of Amlodipine can be decreased when combined with Venlafaxine.	Approved
Amobarbital	The risk or severity of adverse effects can be increased when Amobarbital is combined with Venlafaxine.	Approved, Illicit
Amoxapine	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Amoxapine.	Approved
Amperozide	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Amperozide.	Experimental
Amphetamine	The metabolism of Amphetamine can be decreased when combined with Venlafaxine.	Approved, Illicit
Amprenavir	The metabolism of Amprenavir can be decreased when combined with Venlafaxine.	Approved
Amsacrine	The serum concentration of Venlafaxine can be increased when it is combined with Amsacrine.	Approved
Anagrelide	Venlafaxine may increase the QTc-prolonging activities of Anagrelide.	Approved
Anisodamine	Venlafaxine may increase the tachycardic activities of Anisodamine.	Investigational
Antipyrine	The metabolism of Antipyrine can be decreased when combined with Venlafaxine.	Approved
Apixaban	The serum concentration of Apixaban can be increased when it is combined with Venlafaxine.	Approved
Apomorphine	Venlafaxine may decrease the antihypertensive activities of Apomorphine.	Approved, Investigational
Apraclonidine	Venlafaxine may increase the tachycardic activities of Apraclonidine.	Approved
Apremilast	The metabolism of Apremilast can be decreased when combined with Venlafaxine.	Approved, Investigational
Aprepitant	The serum concentration of Venlafaxine can be increased when it is combined with Aprepitant.	Approved, Investigational
Aprindine	The metabolism of Aprindine can be decreased when combined with Venlafaxine.	Approved
Arbutamine	Venlafaxine may increase the tachycardic activities of Arbutamine.	Approved
Arformoterol	Venlafaxine may increase the tachycardic activities of Arformoterol.	Approved, Investigational
Argatroban	The metabolism of Argatroban can be decreased when combined with Venlafaxine.	Approved, Investigational
Aripiprazole	The serum concentration of Aripiprazole can be increased when it is combined with Venlafaxine.	Approved, Investigational
Armodafinil	The metabolism of Venlafaxine can be decreased when combined with Armodafinil.	Approved, Investigational
Arotinolol	The serum concentration of Arotinolol can be increased when it is combined with Venlafaxine.	Approved
Arsenic trioxide	Venlafaxine may increase the QTc-prolonging activities of Arsenic trioxide.	Approved, Investigational
Artemether	Venlafaxine may increase the QTc-prolonging activities of Artemether.	Approved
Articaine	The risk or severity of adverse effects can be increased when Articaine is combined with Venlafaxine.	Approved
Asenapine	Venlafaxine may increase the QTc-prolonging activities of Asenapine.	Approved
Astemizole	The metabolism of Astemizole can be decreased when combined with Venlafaxine.	Approved, Withdrawn
Atazanavir	The metabolism of Venlafaxine can be decreased when combined with Atazanavir.	Approved, Investigational
Atenolol	The serum concentration of Venlafaxine can be increased when it is combined with Atenolol.	Approved
Atomoxetine	The metabolism of Venlafaxine can be decreased when combined with Atomoxetine.	Approved
Atorvastatin	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Atorvastatin.	Approved
Avanafil	The serum concentration of Avanafil can be increased when it is combined with Venlafaxine.	Approved
Axitinib	The metabolism of Axitinib can be decreased when combined with Venlafaxine.	Approved, Investigational
Azaperone	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Azaperone.	Vet Approved
Azelastine	The metabolism of Azelastine can be decreased when combined with Venlafaxine.	Approved
Azithromycin	Venlafaxine may increase the QTc-prolonging activities of Azithromycin.	Approved
Baclofen	The risk or severity of adverse effects can be increased when Baclofen is combined with Venlafaxine.	Approved
Banoxantrone	The metabolism of Banoxantrone can be decreased when combined with Venlafaxine.	Investigational
Barbital	The risk or severity of adverse effects can be increased when Barbital is combined with Venlafaxine.	Illicit
Bedaquiline	Venlafaxine may increase the QTc-prolonging activities of Bedaquiline.	Approved
Befunolol	Venlafaxine may increase the tachycardic activities of Befunolol.	Experimental
Belinostat	The serum concentration of Belinostat can be increased when it is combined with Venlafaxine.	Approved, Investigational
Bendroflumethiazide	Venlafaxine may increase the hyponatremic activities of Bendroflumethiazide.	Approved
Benmoxin	Benmoxin may increase the serotonergic activities of Venlafaxine.	Withdrawn
Benperidol	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Benperidol.	Investigational
Benzatropine	The metabolism of Benzatropine can be decreased when combined with Venlafaxine.	Approved
Benzocaine	The serum concentration of Venlafaxine can be increased when it is combined with Benzocaine.	Approved
Benzphetamine	The metabolism of Benzphetamine can be decreased when combined with Venlafaxine.	Approved, Illicit
Benzyl alcohol	The metabolism of Benzyl alcohol can be decreased when combined with Venlafaxine.	Approved
Bepridil	The serum concentration of Venlafaxine can be increased when it is combined with Bepridil.	Approved, Withdrawn
Betamethasone	The serum concentration of Betamethasone can be increased when it is combined with Venlafaxine.	Approved, Vet Approved
Betaxolol	The metabolism of Betaxolol can be decreased when combined with Venlafaxine.	Approved
Bethanidine	Venlafaxine may decrease the antihypertensive activities of Bethanidine.	Approved
Bevantolol	The serum concentration of Bevantolol can be increased when it is combined with Venlafaxine.	Approved
Bexarotene	The metabolism of Bexarotene can be decreased when combined with Venlafaxine.	Approved, Investigational
Bezafibrate	The metabolism of Bezafibrate can be decreased when combined with Venlafaxine.	Approved
Bezitramide	Bezitramide may increase the serotonergic activities of Venlafaxine.	Experimental, Illicit, Withdrawn
Bicalutamide	The metabolism of Bicalutamide can be decreased when combined with Venlafaxine.	Approved
Bifeprunox	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Bifeprunox.	Investigational
Biperiden	The serum concentration of Venlafaxine can be increased when it is combined with Biperiden.	Approved
Bisoprolol	The metabolism of Bisoprolol can be decreased when combined with Venlafaxine.	Approved
Bitolterol	Venlafaxine may increase the tachycardic activities of Bitolterol.	Withdrawn
Boceprevir	The metabolism of Venlafaxine can be decreased when combined with Boceprevir.	Withdrawn
Bopindolol	The serum concentration of Bopindolol can be increased when it is combined with Venlafaxine.	Approved
Bortezomib	The metabolism of Venlafaxine can be decreased when combined with Bortezomib.	Approved, Investigational
Bosentan	The serum concentration of Bosentan can be increased when it is combined with Venlafaxine.	Approved, Investigational
Bosutinib	The serum concentration of Bosutinib can be increased when it is combined with Venlafaxine.	Approved
Brentuximab vedotin	The serum concentration of Brentuximab vedotin can be increased when it is combined with Venlafaxine.	Approved
Brexpiprazole	The serum concentration of Brexpiprazole can be increased when it is combined with Venlafaxine.	Approved
Brimonidine	Venlafaxine may increase the tachycardic activities of Brimonidine.	Approved
Brinzolamide	The metabolism of Brinzolamide can be decreased when combined with Venlafaxine.	Approved
Brivaracetam	The metabolism of Brivaracetam can be decreased when combined with Venlafaxine.	Approved, Investigational
Brofaromine	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Brofaromine.	Experimental
Bromazepam	The metabolism of Bromazepam can be decreased when combined with Venlafaxine.	Approved, Illicit
Bromisoval	The risk or severity of adverse effects can be increased when Bromisoval is combined with Venlafaxine.	Experimental
Bromocriptine	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Bromocriptine.	Approved, Investigational
Bromperidol	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Bromperidol.	Investigational
Brompheniramine	The metabolism of Brompheniramine can be decreased when combined with Venlafaxine.	Approved
Brotizolam	The risk or severity of adverse effects can be increased when Brotizolam is combined with Venlafaxine.	Approved, Withdrawn
Bucindolol	The serum concentration of Bucindolol can be increased when it is combined with Venlafaxine.	Investigational
Budesonide	The serum concentration of Budesonide can be increased when it is combined with Venlafaxine.	Approved
Bufuralol	The metabolism of Bufuralol can be decreased when combined with Venlafaxine.	Experimental, Investigational
Bupivacaine	The metabolism of Bupivacaine can be decreased when combined with Venlafaxine.	Approved, Investigational
Bupranolol	The serum concentration of Bupranolol can be increased when it is combined with Venlafaxine.	Approved
Buprenorphine	The metabolism of Buprenorphine can be decreased when combined with Venlafaxine.	Approved, Illicit, Investigational, Vet Approved
Bupropion	The serum concentration of Bupropion can be increased when it is combined with Venlafaxine.	Approved
Buspirone	Buspirone may increase the serotonergic activities of Venlafaxine.	Approved, Investigational
Busulfan	The metabolism of Busulfan can be decreased when combined with Venlafaxine.	Approved, Investigational
Butabarbital	The risk or severity of adverse effects can be increased when Butabarbital is combined with Venlafaxine.	Approved, Illicit
Butacaine	The risk or severity of adverse effects can be increased when Butacaine is combined with Venlafaxine.	Vet Approved
Butalbital	The risk or severity of adverse effects can be increased when Butalbital is combined with Venlafaxine.	Approved, Illicit
Butamben	The risk or severity of adverse effects can be increased when Butamben is combined with Venlafaxine.	Approved
Butaperazine	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Butaperazine.	Experimental
Butethal	The risk or severity of adverse effects can be increased when Butethal is combined with Venlafaxine.	Approved, Illicit
Butorphanol	Butorphanol may increase the serotonergic activities of Venlafaxine.	Approved, Illicit, Vet Approved
Cabazitaxel	The metabolism of Cabazitaxel can be decreased when combined with Venlafaxine.	Approved
Cabergoline	The risk or severity of adverse effects can be increased when Cabergoline is combined with Venlafaxine.	Approved
Cabozantinib	The metabolism of Cabozantinib can be decreased when combined with Venlafaxine.	Approved
Caffeine	The metabolism of Caffeine can be decreased when combined with Venlafaxine.	Approved
Calcitriol	The metabolism of Calcitriol can be decreased when combined with Venlafaxine.	Approved, Nutraceutical
Camptothecin	The serum concentration of Camptothecin can be increased when it is combined with Venlafaxine.	Experimental
Canagliflozin	The metabolism of Canagliflozin can be decreased when combined with Venlafaxine.	Approved
Candesartan cilexetil	The serum concentration of Venlafaxine can be increased when it is combined with Candesartan.	Approved
Canertinib	The risk or severity of adverse effects can be increased when Canertinib is combined with Venlafaxine.	Investigational
Capecitabine	The metabolism of Venlafaxine can be decreased when combined with Capecitabine.	Approved, Investigational
Captopril	The serum concentration of Venlafaxine can be increased when it is combined with Captopril.	Approved
Carbamazepine	The metabolism of Carbamazepine can be decreased when combined with Venlafaxine.	Approved, Investigational
Carbinoxamine	The metabolism of Carbinoxamine can be decreased when combined with Venlafaxine.	Approved
Carfentanil	Carfentanil may increase the serotonergic activities of Venlafaxine.	Illicit, Vet Approved
Carfilzomib	The serum concentration of Carfilzomib can be increased when it is combined with Venlafaxine.	Approved
Cariprazine	The metabolism of Cariprazine can be decreased when combined with Venlafaxine.	Approved
Carisoprodol	The risk or severity of adverse effects can be increased when Carisoprodol is combined with Venlafaxine.	Approved
Caroxazone	Caroxazone may increase the serotonergic activities of Venlafaxine.	Withdrawn
Carteolol	The metabolism of Carteolol can be decreased when combined with Venlafaxine.	Approved
Carvedilol	The metabolism of Carvedilol can be decreased when combined with Venlafaxine.	Approved, Investigational
Caspofungin	The serum concentration of Venlafaxine can be increased when it is combined with Caspofungin.	Approved
Celecoxib	Venlafaxine may increase the antiplatelet activities of Celecoxib.	Approved, Investigational
Celiprolol	The metabolism of Celiprolol can be decreased when combined with Venlafaxine.	Approved, Investigational
Cephalexin	The metabolism of Cephalexin can be decreased when combined with Venlafaxine.	Approved, Vet Approved
Ceritinib	The serum concentration of Venlafaxine can be increased when it is combined with Ceritinib.	Approved
Cerivastatin	The metabolism of Cerivastatin can be decreased when combined with Venlafaxine.	Withdrawn
Cetirizine	The risk or severity of adverse effects can be increased when Cetirizine is combined with Venlafaxine.	Approved
Cevimeline	The metabolism of Cevimeline can be decreased when combined with Venlafaxine.	Approved
Chenodeoxycholic acid	The metabolism of Chenodeoxycholic acid can be decreased when combined with Venlafaxine.	Approved
Chloral hydrate	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Venlafaxine.	Approved, Illicit, Vet Approved
Chloramphenicol	The metabolism of Venlafaxine can be decreased when combined with Chloramphenicol.	Approved, Vet Approved
Chlordiazepoxide	The metabolism of Chlordiazepoxide can be decreased when combined with Venlafaxine.	Approved, Illicit
Chlormezanone	The risk or severity of adverse effects can be increased when Chlormezanone is combined with Venlafaxine.	Approved, Withdrawn
Chloroprocaine	The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Venlafaxine.	Approved
Chloroquine	Venlafaxine may increase the QTc-prolonging activities of Chloroquine.	Approved, Vet Approved
Chlorothiazide	Venlafaxine may increase the hyponatremic activities of Chlorothiazide.	Approved, Vet Approved
Chlorphenamine	The metabolism of Chlorphenamine can be decreased when combined with Venlafaxine.	Approved
Chlorproethazine	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Chlorproethazine.	Experimental
Chlorpromazine	Venlafaxine may increase the QTc-prolonging activities of Chlorpromazine.	Approved, Vet Approved
Chlorpropamide	The serum concentration of Venlafaxine can be increased when it is combined with Chlorpropamide.	Approved
Chlorprothixene	The serum concentration of Venlafaxine can be increased when it is combined with Chlorprothixene.	Approved, Withdrawn
Chlorthalidone	Venlafaxine may increase the hyponatremic activities of Chlorthalidone.	Approved
Chlorzoxazone	The metabolism of Chlorzoxazone can be decreased when combined with Venlafaxine.	Approved
Cholecalciferol	The metabolism of Cholecalciferol can be decreased when combined with Venlafaxine.	Approved, Nutraceutical
Cholesterol	The serum concentration of Venlafaxine can be increased when it is combined with Cholesterol.	Experimental
Cholic Acid	The serum concentration of Venlafaxine can be decreased when it is combined with Cholic Acid.	Approved
Ciclesonide	The metabolism of Ciclesonide can be decreased when combined with Venlafaxine.	Approved, Investigational
Cilazapril	The serum concentration of Venlafaxine can be increased when it is combined with Cilazapril.	Approved
Cilostazol	The serum concentration of Cilostazol can be increased when it is combined with Venlafaxine.	Approved
Cimetidine	The metabolism of Venlafaxine can be decreased when combined with Cimetidine.	Approved
Cinacalcet	The metabolism of Venlafaxine can be decreased when combined with Cinacalcet.	Approved
Cinchocaine	The risk or severity of adverse effects can be increased when Cinchocaine is combined with Venlafaxine.	Approved, Vet Approved
Cinnarizine	The metabolism of Cinnarizine can be decreased when combined with Venlafaxine.	Approved
Ciprofloxacin	Venlafaxine may increase the QTc-prolonging activities of Ciprofloxacin.	Approved, Investigational
Cirazoline	Venlafaxine may increase the tachycardic activities of Cirazoline.	Experimental
Cisapride	Venlafaxine may increase the QTc-prolonging activities of Cisapride.	Approved, Investigational, Withdrawn
Cisplatin	The serum concentration of Cisplatin can be increased when it is combined with Venlafaxine.	Approved
Citalopram	Venlafaxine may increase the QTc-prolonging activities of Citalopram.	Approved
Clarithromycin	The metabolism of Venlafaxine can be decreased when combined with Clarithromycin.	Approved
Clemastine	The metabolism of Venlafaxine can be decreased when combined with Clemastine.	Approved
Clenbuterol	Venlafaxine may increase the tachycardic activities of Clenbuterol.	Approved, Vet Approved
Clevidipine	The metabolism of Clevidipine can be decreased when combined with Venlafaxine.	Approved
Clidinium	The risk or severity of adverse effects can be increased when Clidinium is combined with Venlafaxine.	Approved
Clindamycin	The metabolism of Clindamycin can be decreased when combined with Venlafaxine.	Approved, Vet Approved
Clobazam	The metabolism of Clobazam can be decreased when combined with Venlafaxine.	Approved, Illicit
Clofazimine	The metabolism of Clofazimine can be decreased when combined with Venlafaxine.	Approved, Investigational
Clofibrate	The metabolism of Clofibrate can be decreased when combined with Venlafaxine.	Approved
clomethiazole	The metabolism of clomethiazole can be decreased when combined with Venlafaxine.	Investigational
Clomifene	The serum concentration of Clomifene can be increased when it is combined with Venlafaxine.	Approved, Investigational
Clomipramine	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Clomipramine.	Approved, Vet Approved
Clonazepam	The metabolism of Clonazepam can be decreased when combined with Venlafaxine.	Approved, Illicit
Clonidine	Venlafaxine may increase the tachycardic activities of Clonidine.	Approved
Clopenthixol	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Clopenthixol.	Experimental
Clopidogrel	The metabolism of Clopidogrel can be decreased when combined with Venlafaxine.	Approved, Nutraceutical
Cloranolol	The serum concentration of Cloranolol can be increased when it is combined with Venlafaxine.	Experimental
Clorazepate	The metabolism of Clorazepate can be decreased when combined with Venlafaxine.	Approved, Illicit
Clorindione	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Clorindione.	Experimental
Clothiapine	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Clothiapine.	Experimental
Clotiazepam	The metabolism of Clotiazepam can be decreased when combined with Venlafaxine.	Approved, Illicit
Clotrimazole	The metabolism of Venlafaxine can be decreased when combined with Clotrimazole.	Approved, Vet Approved
Clozapine	The serum concentration of Clozapine can be increased when it is combined with Venlafaxine.	Approved
Cobicistat	The serum concentration of Venlafaxine can be increased when it is combined with Cobicistat.	Approved
Cobimetinib	The serum concentration of Cobimetinib can be increased when it is combined with Venlafaxine.	Approved
Cocaine	The metabolism of Venlafaxine can be decreased when combined with Cocaine.	Approved, Illicit
Codeine	The therapeutic efficacy of Codeine can be decreased when used in combination with Venlafaxine.	Approved, Illicit
Colchicine	The serum concentration of Colchicine can be increased when it is combined with Venlafaxine.	Approved
Colforsin	The serum concentration of Venlafaxine can be increased when it is combined with Colforsin.	Experimental
Conivaptan	The serum concentration of Venlafaxine can be increased when it is combined with Conivaptan.	Approved, Investigational
Conjugated estrogens	The metabolism of Conjugated estrogens can be decreased when combined with Venlafaxine.	Approved
Copanlisib	The metabolism of Copanlisib can be decreased when combined with Venlafaxine.	Approved
Cortisone acetate	The metabolism of Cortisone acetate can be decreased when combined with Venlafaxine.	Approved
Crisaborole	The metabolism of Venlafaxine can be decreased when combined with Crisaborole.	Approved
Crizotinib	Venlafaxine may increase the QTc-prolonging activities of Crizotinib.	Approved
Cyamemazine	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Cyamemazine.	Approved
Cyclizine	The risk or severity of adverse effects can be increased when Cyclizine is combined with Venlafaxine.	Approved
Cyclobenzaprine	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Cyclobenzaprine.	Approved
Cyclopenthiazide	Venlafaxine may increase the hyponatremic activities of Cyclopenthiazide.	Experimental
Cyclophosphamide	The metabolism of Cyclophosphamide can be decreased when combined with Venlafaxine.	Approved, Investigational
Cyclosporine	The metabolism of Cyclosporine can be decreased when combined with Venlafaxine.	Approved, Investigational, Vet Approved
Cyproheptadine	The therapeutic efficacy of Venlafaxine can be decreased when used in combination with Cyproheptadine.	Approved
Cytarabine	The metabolism of Cytarabine can be decreased when combined with Venlafaxine.	Approved, Investigational
Dabigatran etexilate	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Venlafaxine.	Approved
Dabrafenib	The serum concentration of Venlafaxine can be decreased when it is combined with Dabrafenib.	Approved
Daclatasvir	The metabolism of Daclatasvir can be decreased when combined with Venlafaxine.	Approved
Dactinomycin	The serum concentration of Venlafaxine can be increased when it is combined with Dactinomycin.	Approved
Dantrolene	The metabolism of Dantrolene can be decreased when combined with Venlafaxine.	Approved
Dapagliflozin	The metabolism of Dapagliflozin can be decreased when combined with Venlafaxine.	Approved
Dapiprazole	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Dapiprazole.	Approved
Dapoxetine	The serum concentration of Dapoxetine can be increased when it is combined with Venlafaxine.	Investigational
Dapsone	The metabolism of Dapsone can be decreased when combined with Venlafaxine.	Approved, Investigational
Darifenacin	The metabolism of Darifenacin can be decreased when combined with Venlafaxine.	Approved, Investigational
Darunavir	The serum concentration of Venlafaxine can be increased when it is combined with Darunavir.	Approved
Dasabuvir	The metabolism of Dasabuvir can be decreased when combined with Venlafaxine.	Approved
Dasatinib	The serum concentration of Venlafaxine can be increased when it is combined with Dasatinib.	Approved, Investigational
Daunorubicin	The metabolism of Daunorubicin can be decreased when combined with Venlafaxine.	Approved
Debrisoquin	The serum concentration of Debrisoquin can be increased when it is combined with Venlafaxine.	Approved
Deferasirox	The serum concentration of Venlafaxine can be decreased when it is combined with Deferasirox.	Approved, Investigational
Deflazacort	The metabolism of Deflazacort can be decreased when combined with Venlafaxine.	Approved
Delavirdine	The metabolism of Venlafaxine can be decreased when combined with Delavirdine.	Approved
Deramciclane	The risk or severity of adverse effects can be increased when Deramciclane is combined with Venlafaxine.	Investigational
Desflurane	The risk or severity of adverse effects can be increased when Desflurane is combined with Venlafaxine.	Approved
Desipramine	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Desipramine.	Approved
Desloratadine	The serum concentration of Venlafaxine can be increased when it is combined with Desloratadine.	Approved, Investigational
Desmopressin	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Desmopressin.	Approved
Desvenlafaxine	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Desvenlafaxine.	Approved
Detomidine	Venlafaxine may increase the tachycardic activities of Detomidine.	Vet Approved
Deutetrabenazine	The metabolism of Deutetrabenazine can be decreased when combined with Venlafaxine.	Approved, Investigational
Dexamethasone	The metabolism of Dexamethasone can be decreased when combined with Venlafaxine.	Approved, Investigational, Vet Approved
Dexbrompheniramine	The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Venlafaxine.	Approved
Dexchlorpheniramine maleate	The metabolism of Dexchlorpheniramine maleate can be decreased when combined with Venlafaxine.	Approved
Dexfenfluramine	The metabolism of Dexfenfluramine can be decreased when combined with Venlafaxine.	Approved, Illicit, Withdrawn
Dexlansoprazole	The metabolism of Dexlansoprazole can be decreased when combined with Venlafaxine.	Approved
Dexmedetomidine	Venlafaxine may increase the tachycardic activities of Dexmedetomidine.	Approved, Vet Approved
Dexmethylphenidate	The metabolism of Dexmethylphenidate can be decreased when combined with Venlafaxine.	Approved
Dextroamphetamine	The metabolism of Dextroamphetamine can be decreased when combined with Venlafaxine.	Approved, Illicit
Dextromethorphan	Venlafaxine may increase the serotonergic activities of Dextromethorphan.	Approved
Dextromoramide	Dextromoramide may increase the serotonergic activities of Venlafaxine.	Experimental, Illicit
Dextropropoxyphene	The metabolism of Dextropropoxyphene can be decreased when combined with Venlafaxine.	Approved, Illicit, Withdrawn
Dezocine	Dezocine may increase the serotonergic activities of Venlafaxine.	Approved
Diazepam	The metabolism of Diazepam can be decreased when combined with Venlafaxine.	Approved, Illicit, Vet Approved
Diclofenac	The metabolism of Diclofenac can be decreased when combined with Venlafaxine.	Approved, Vet Approved
Dicoumarol	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Dicoumarol.	Approved
Dienogest	The metabolism of Dienogest can be decreased when combined with Venlafaxine.	Approved
Diethyl ether	The risk or severity of adverse effects can be increased when Diethyl ether is combined with Venlafaxine.	Experimental
Diethylstilbestrol	The serum concentration of Diethylstilbestrol can be increased when it is combined with Venlafaxine.	Approved
Difenoxin	The risk or severity of adverse effects can be increased when Difenoxin is combined with Venlafaxine.	Approved, Illicit
Digitoxin	The metabolism of Digitoxin can be decreased when combined with Venlafaxine.	Approved
Digoxin	The metabolism of Digoxin can be decreased when combined with Venlafaxine.	Approved
Dihydrocodeine	The metabolism of Dihydrocodeine can be decreased when combined with Venlafaxine.	Approved, Illicit
Dihydroergocornine	The risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Venlafaxine.	Approved
Dihydroergocristine	The risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Venlafaxine.	Experimental
Dihydroergocryptine	The risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Venlafaxine.	Experimental
Dihydroergotamine	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Dihydroergotamine.	Approved
Dihydroetorphine	Dihydroetorphine may increase the serotonergic activities of Venlafaxine.	Experimental, Illicit
Dihydromorphine	Dihydromorphine may increase the serotonergic activities of Venlafaxine.	Experimental, Illicit
Dihydrotestosterone	The serum concentration of Dihydrotestosterone can be increased when it is combined with Venlafaxine.	Illicit
Diltiazem	The metabolism of Venlafaxine can be decreased when combined with Diltiazem.	Approved
Dimenhydrinate	The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Venlafaxine.	Approved
Diphenadione	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Diphenadione.	Experimental
Diphenhydramine	The metabolism of Diphenhydramine can be decreased when combined with Venlafaxine.	Approved
Diphenoxylate	Diphenoxylate may increase the serotonergic activities of Venlafaxine.	Approved, Illicit
Dipivefrin	Venlafaxine may increase the tachycardic activities of Dipivefrin.	Approved
Dipyridamole	The serum concentration of Venlafaxine can be increased when it is combined with Dipyridamole.	Approved
Disopyramide	Venlafaxine may increase the QTc-prolonging activities of Disopyramide.	Approved
Disulfiram	The metabolism of Disulfiram can be decreased when combined with Venlafaxine.	Approved
Dixyrazine	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Dixyrazine.	Experimental
Dobutamine	Venlafaxine may increase the tachycardic activities of Dobutamine.	Approved
Docetaxel	The metabolism of Docetaxel can be decreased when combined with Venlafaxine.	Approved, Investigational
Dofetilide	The serum concentration of Dofetilide can be increased when it is combined with Venlafaxine.	Approved
Dolasetron	Venlafaxine may increase the QTc-prolonging activities of Dolasetron.	Approved
Domperidone	The serum concentration of Domperidone can be increased when it is combined with Venlafaxine.	Approved, Investigational, Vet Approved
Donepezil	The metabolism of Donepezil can be decreased when combined with Venlafaxine.	Approved
Dopamine	The metabolism of Dopamine can be decreased when combined with Venlafaxine.	Approved
Dopexamine	Venlafaxine may increase the tachycardic activities of Dopexamine.	Investigational
Doramectin	The risk or severity of adverse effects can be increased when Doramectin is combined with Venlafaxine.	Vet Approved
Dorzolamide	The metabolism of Dorzolamide can be decreased when combined with Venlafaxine.	Approved
Dosulepin	The serum concentration of Dosulepin can be increased when it is combined with Venlafaxine.	Approved
Doxazosin	The serum concentration of Venlafaxine can be increased when it is combined with Doxazosin.	Approved
Doxepin	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Doxepin.	Approved
Doxorubicin	The serum concentration of Doxorubicin can be increased when it is combined with Venlafaxine.	Approved, Investigational
Doxorubicin	The metabolism of Doxorubicin can be decreased when combined with Venlafaxine.	Approved, Investigational
Doxycycline	The metabolism of Venlafaxine can be decreased when combined with Doxycycline.	Approved, Investigational, Vet Approved
Doxylamine	The risk or severity of adverse effects can be increased when Doxylamine is combined with Venlafaxine.	Approved, Vet Approved
DPDPE	DPDPE may increase the serotonergic activities of Venlafaxine.	Investigational
Dronabinol	The serum concentration of Dronabinol can be increased when it is combined with Venlafaxine.	Approved, Illicit
Dronedarone	Venlafaxine may increase the QTc-prolonging activities of Dronedarone.	Approved
Droperidol	Venlafaxine may increase the QTc-prolonging activities of Droperidol.	Approved, Vet Approved
Drotebanol	The risk or severity of adverse effects can be increased when Drotebanol is combined with Venlafaxine.	Experimental, Illicit
Droxidopa	Venlafaxine may increase the tachycardic activities of Droxidopa.	Approved, Investigational
Dulaglutide	Venlafaxine may increase the hypoglycemic activities of Dulaglutide.	Approved
Duloxetine	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Duloxetine.	Approved
Dutasteride	The metabolism of Dutasteride can be decreased when combined with Venlafaxine.	Approved, Investigational
Dyclonine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Venlafaxine.	Approved
Ecgonine	The risk or severity of adverse effects can be increased when Ecgonine is combined with Venlafaxine.	Experimental, Illicit
Ecopipam	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Ecopipam.	Investigational
Edoxaban	The serum concentration of Edoxaban can be increased when it is combined with Venlafaxine.	Approved
Efavirenz	The metabolism of Efavirenz can be decreased when combined with Venlafaxine.	Approved, Investigational
Elbasvir	The serum concentration of Elbasvir can be increased when it is combined with Venlafaxine.	Approved
Eletriptan	The serum concentration of Eletriptan can be increased when it is combined with Venlafaxine.	Approved, Investigational
Eliglustat	The serum concentration of Eliglustat can be increased when it is combined with Venlafaxine.	Approved
Eltanolone	The risk or severity of adverse effects can be increased when Eltanolone is combined with Venlafaxine.	Investigational
Elvitegravir	The metabolism of Elvitegravir can be decreased when combined with Venlafaxine.	Approved
Empagliflozin	Venlafaxine may increase the hypoglycemic activities of Empagliflozin.	Approved
Enalapril	The metabolism of Enalapril can be decreased when combined with Venlafaxine.	Approved, Vet Approved
Enasidenib	The metabolism of Enasidenib can be decreased when combined with Venlafaxine.	Approved
Encainide	The metabolism of Encainide can be decreased when combined with Venlafaxine.	Approved, Withdrawn
Enclomiphene	The metabolism of Enclomiphene can be decreased when combined with Venlafaxine.	Investigational
Enflurane	The risk or severity of adverse effects can be increased when Enflurane is combined with Venlafaxine.	Approved, Vet Approved
Entacapone	The risk or severity of adverse effects can be increased when Entacapone is combined with Venlafaxine.	Approved, Investigational
Enzalutamide	The serum concentration of Venlafaxine can be decreased when it is combined with Enzalutamide.	Approved
Epanolol	The serum concentration of Epanolol can be increased when it is combined with Venlafaxine.	Experimental
Ephedra	Venlafaxine may decrease the antihypertensive activities of Ephedra.	Approved, Nutraceutical, Withdrawn
Ephedrine	Venlafaxine may increase the tachycardic activities of Ephedrine.	Approved
Epinastine	The metabolism of Epinastine can be decreased when combined with Venlafaxine.	Approved, Investigational
Epinephrine	Venlafaxine may increase the tachycardic activities of Epinephrine.	Approved, Vet Approved
Eplerenone	The serum concentration of Eplerenone can be increased when it is combined with Venlafaxine.	Approved
Ergocalciferol	The metabolism of Ergocalciferol can be decreased when combined with Venlafaxine.	Approved, Nutraceutical
Ergoloid mesylate	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Ergoloid mesylate.	Approved
Ergonovine	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Ergonovine.	Approved
Ergotamine	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Ergotamine.	Approved
Erlotinib	The metabolism of Erlotinib can be decreased when combined with Venlafaxine.	Approved, Investigational
Erythromycin	Venlafaxine may increase the QTc-prolonging activities of Erythromycin.	Approved, Vet Approved
Escitalopram	Venlafaxine may increase the QTc-prolonging activities of Escitalopram.	Approved, Investigational
Eslicarbazepine acetate	The metabolism of Venlafaxine can be decreased when combined with Eslicarbazepine acetate.	Approved
Esmirtazapine	The metabolism of Esmirtazapine can be decreased when combined with Venlafaxine.	Investigational
Esmolol	The serum concentration of Esmolol can be increased when it is combined with Venlafaxine.	Approved
Esomeprazole	The metabolism of Esomeprazole can be decreased when combined with Venlafaxine.	Approved, Investigational
Estazolam	The metabolism of Estazolam can be decreased when combined with Venlafaxine.	Approved, Illicit
Estradiol	The metabolism of Estradiol can be decreased when combined with Venlafaxine.	Approved, Investigational, Vet Approved
Estradiol valerate/Dienogest	The metabolism of Estradiol valerate/Dienogest can be decreased when combined with Venlafaxine.	Approved
Estramustine	The metabolism of Estramustine can be decreased when combined with Venlafaxine.	Approved
Estriol	The serum concentration of Venlafaxine can be decreased when it is combined with Estriol.	Approved, Vet Approved
Estrogens, esterified	The metabolism of Estrogens, esterified can be decreased when combined with Venlafaxine.	Approved
Estrone	The metabolism of Estrone can be decreased when combined with Venlafaxine.	Approved
Estrone sulfate	The metabolism of Estrone sulfate can be decreased when combined with Venlafaxine.	Approved
Eszopiclone	The metabolism of Eszopiclone can be decreased when combined with Venlafaxine.	Approved
Ethanol	The risk or severity of adverse effects can be increased when Ethanol is combined with Venlafaxine.	Approved
Ethchlorvynol	The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Venlafaxine.	Approved, Illicit, Withdrawn
Ethinyl Estradiol	The metabolism of Ethinyl Estradiol can be decreased when combined with Venlafaxine.	Approved
Ethosuximide	The metabolism of Ethosuximide can be decreased when combined with Venlafaxine.	Approved
Ethotoin	The risk or severity of adverse effects can be increased when Ethotoin is combined with Venlafaxine.	Approved
Ethyl biscoumacetate	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Ethyl biscoumacetate.	Withdrawn
Ethyl carbamate	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Venlafaxine.	Withdrawn
Ethyl chloride	The risk or severity of adverse effects can be increased when Ethyl chloride is combined with Venlafaxine.	Experimental
Ethyl loflazepate	The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Venlafaxine.	Approved, Illicit
Ethylmorphine	The metabolism of Ethylmorphine can be decreased when combined with Venlafaxine.	Approved, Illicit
Etidocaine	The risk or severity of adverse effects can be increased when Etidocaine is combined with Venlafaxine.	Approved
Etifoxine	The risk or severity of adverse effects can be increased when Etifoxine is combined with Venlafaxine.	Withdrawn
Etilefrine	Venlafaxine may increase the tachycardic activities of Etilefrine.	Withdrawn
Etizolam	The risk or severity of adverse effects can be increased when Etizolam is combined with Venlafaxine.	Approved
Etodolac	Venlafaxine may increase the antiplatelet activities of Etodolac.	Approved, Investigational, Vet Approved
Etomidate	Venlafaxine may decrease the antihypertensive activities of Etomidate.	Approved
Etonogestrel	The metabolism of Etonogestrel can be decreased when combined with Venlafaxine.	Approved, Investigational
Etoposide	The metabolism of Etoposide can be decreased when combined with Venlafaxine.	Approved
Etoricoxib	Venlafaxine may increase the antiplatelet activities of Etoricoxib.	Approved, Investigational
Etorphine	Etorphine may increase the serotonergic activities of Venlafaxine.	Illicit, Vet Approved
Etravirine	The metabolism of Etravirine can be decreased when combined with Venlafaxine.	Approved
Everolimus	The serum concentration of Everolimus can be increased when it is combined with Venlafaxine.	Approved
Exemestane	The metabolism of Exemestane can be decreased when combined with Venlafaxine.	Approved, Investigational
Exenatide	Venlafaxine may increase the hypoglycemic activities of Exenatide.	Approved, Investigational
Ezetimibe	The serum concentration of Ezetimibe can be increased when it is combined with Venlafaxine.	Approved
Ezogabine	The risk or severity of adverse effects can be increased when Ezogabine is combined with Venlafaxine.	Approved
Famciclovir	The metabolism of Famciclovir can be decreased when combined with Venlafaxine.	Approved
Felbamate	The metabolism of Felbamate can be decreased when combined with Venlafaxine.	Approved
Felodipine	The metabolism of Felodipine can be decreased when combined with Venlafaxine.	Approved, Investigational
Fencamfamine	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Fencamfamine.	Approved, Illicit, Withdrawn
Fenfluramine	Venlafaxine may increase the serotonergic activities of Fenfluramine.	Illicit, Withdrawn
Fenofibrate	The metabolism of Fenofibrate can be decreased when combined with Venlafaxine.	Approved
Fenoterol	Venlafaxine may increase the tachycardic activities of Fenoterol.	Approved
Fentanyl	The serum concentration of Fentanyl can be increased when it is combined with Venlafaxine.	Approved, Illicit, Investigational, Vet Approved
Fesoterodine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Venlafaxine.	Approved
Fexofenadine	The serum concentration of Fexofenadine can be increased when it is combined with Venlafaxine.	Approved
Fidaxomicin	The serum concentration of Fidaxomicin can be increased when it is combined with Venlafaxine.	Approved
Finasteride	The metabolism of Finasteride can be decreased when combined with Venlafaxine.	Approved
Fingolimod	The metabolism of Fingolimod can be decreased when combined with Venlafaxine.	Approved, Investigational
Flecainide	Venlafaxine may increase the QTc-prolonging activities of Flecainide.	Approved, Withdrawn
Flibanserin	The serum concentration of Flibanserin can be increased when it is combined with Venlafaxine.	Approved
Floxuridine	The metabolism of Venlafaxine can be decreased when combined with Floxuridine.	Approved
Fluanisone	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Fluanisone.	Experimental
Fluconazole	The metabolism of Venlafaxine can be decreased when combined with Fluconazole.	Approved
Fludiazepam	The risk or severity of adverse effects can be increased when Fludiazepam is combined with Venlafaxine.	Approved, Illicit
Fluindione	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Fluindione.	Investigational
Flunarizine	The metabolism of Flunarizine can be decreased when combined with Venlafaxine.	Approved
Flunisolide	The metabolism of Flunisolide can be decreased when combined with Venlafaxine.	Approved, Investigational
Flunitrazepam	The metabolism of Flunitrazepam can be decreased when combined with Venlafaxine.	Approved, Illicit
Fluorometholone	The metabolism of Fluorometholone can be decreased when combined with Venlafaxine.	Approved
Fluorouracil	The metabolism of Venlafaxine can be decreased when combined with Fluorouracil.	Approved
Fluoxetine	Venlafaxine may increase the QTc-prolonging activities of Fluoxetine.	Approved, Vet Approved
Flupentixol	Venlafaxine may increase the QTc-prolonging activities of Flupentixol.	Approved, Withdrawn
Fluphenazine	The serum concentration of Venlafaxine can be increased when it is combined with Fluphenazine.	Approved
Flurazepam	The metabolism of Flurazepam can be decreased when combined with Venlafaxine.	Approved, Illicit
Fluspirilene	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Fluspirilene.	Approved
Flutamide	The metabolism of Flutamide can be decreased when combined with Venlafaxine.	Approved
Fluticasone furoate	The metabolism of Fluticasone furoate can be decreased when combined with Venlafaxine.	Approved
Fluticasone propionate	The metabolism of Fluticasone propionate can be decreased when combined with Venlafaxine.	Approved
Fluvastatin	The metabolism of Fluvastatin can be decreased when combined with Venlafaxine.	Approved
Fluvoxamine	The metabolism of Venlafaxine can be decreased when combined with Fluvoxamine.	Approved, Investigational
Formoterol	Venlafaxine may increase the tachycardic activities of Formoterol.	Approved, Investigational
Fosamprenavir	The metabolism of Fosamprenavir can be decreased when combined with Venlafaxine.	Approved
Fosaprepitant	The serum concentration of Venlafaxine can be increased when it is combined with Fosaprepitant.	Approved
Fosphenytoin	The metabolism of Venlafaxine can be increased when combined with Fosphenytoin.	Approved
Fospropofol	The risk or severity of adverse effects can be increased when Fospropofol is combined with Venlafaxine.	Approved, Illicit
Frovatriptan	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Frovatriptan.	Approved, Investigational
Fulvestrant	The metabolism of Fulvestrant can be decreased when combined with Venlafaxine.	Approved, Investigational
Furazolidone	Furazolidone may increase the serotonergic activities of Venlafaxine.	Approved, Vet Approved
Fusidic Acid	The serum concentration of Venlafaxine can be increased when it is combined with Fusidic Acid.	Approved
Gabapentin	The risk or severity of adverse effects can be increased when Gabapentin is combined with Venlafaxine.	Approved, Investigational
Gabapentin Enacarbil	The risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Venlafaxine.	Approved
Gadobenic acid	Venlafaxine may increase the QTc-prolonging activities of Gadobenic acid.	Approved
Galantamine	The metabolism of Galantamine can be decreased when combined with Venlafaxine.	Approved
Gamma Hydroxybutyric Acid	The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Venlafaxine.	Approved, Illicit
Gefitinib	The metabolism of Gefitinib can be decreased when combined with Venlafaxine.	Approved, Investigational
Gemcitabine	The serum concentration of Gemcitabine can be increased when it is combined with Venlafaxine.	Approved
Gemfibrozil	The metabolism of Venlafaxine can be decreased when combined with Gemfibrozil.	Approved
Gemifloxacin	Venlafaxine may increase the QTc-prolonging activities of Gemifloxacin.	Approved, Investigational
Genistein	The serum concentration of Venlafaxine can be increased when it is combined with Genistein.	Investigational
Gepirone	The risk or severity of adverse effects can be increased when Gepirone is combined with Venlafaxine.	Investigational
Glecaprevir	The serum concentration of Glecaprevir can be increased when it is combined with Venlafaxine.	Approved
Gliclazide	Venlafaxine may increase the hypoglycemic activities of Gliclazide.	Approved
Glimepiride	Venlafaxine may increase the hypoglycemic activities of Glimepiride.	Approved
Glipizide	The metabolism of Glipizide can be decreased when combined with Venlafaxine.	Approved
Glutethimide	The risk or severity of adverse effects can be increased when Glutethimide is combined with Venlafaxine.	Approved, Illicit
Glyburide	The metabolism of Glyburide can be decreased when combined with Venlafaxine.	Approved
Glycerin	The serum concentration of Venlafaxine can be increased when it is combined with Glycerin.	Approved, Investigational
Goserelin	Venlafaxine may increase the QTc-prolonging activities of Goserelin.	Approved
Gramicidin D	The serum concentration of Venlafaxine can be increased when it is combined with Gramicidin D.	Approved
Granisetron	Venlafaxine may increase the QTc-prolonging activities of Granisetron.	Approved, Investigational
Grazoprevir	The serum concentration of Grazoprevir can be increased when it is combined with Venlafaxine.	Approved
Grepafloxacin	The metabolism of Grepafloxacin can be decreased when combined with Venlafaxine.	Withdrawn
Guanabenz	Venlafaxine may increase the tachycardic activities of Guanabenz.	Approved
Guanfacine	Venlafaxine may increase the tachycardic activities of Guanfacine.	Approved, Investigational
Halazepam	The risk or severity of adverse effects can be increased when Halazepam is combined with Venlafaxine.	Approved, Illicit, Withdrawn
Halofantrine	The serum concentration of Halofantrine can be increased when it is combined with Venlafaxine.	Approved
Haloperidol	Venlafaxine may increase the QTc-prolonging activities of Haloperidol.	Approved
Halothane	The metabolism of Halothane can be decreased when combined with Venlafaxine.	Approved, Vet Approved
Harmaline	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Harmaline.	Experimental
Heroin	Heroin may increase the serotonergic activities of Venlafaxine.	Approved, Illicit
Hexobarbital	The metabolism of Hexobarbital can be decreased when combined with Venlafaxine.	Approved
Hexoprenaline	Venlafaxine may increase the tachycardic activities of Hexoprenaline.	Approved, Withdrawn
Higenamine	Venlafaxine may increase the tachycardic activities of Higenamine.	Investigational
Histamine	The metabolism of Histamine can be decreased when combined with Venlafaxine.	Approved, Investigational
Hydracarbazine	Hydracarbazine may increase the serotonergic activities of Venlafaxine.	Experimental
Hydrochlorothiazide	Venlafaxine may increase the hyponatremic activities of Hydrochlorothiazide.	Approved, Vet Approved
Hydrocodone	The serum concentration of Hydrocodone can be increased when it is combined with Venlafaxine.	Approved, Illicit
Hydrocortisone	The metabolism of Hydrocortisone can be decreased when combined with Venlafaxine.	Approved, Vet Approved
Hydroflumethiazide	Venlafaxine may increase the hyponatremic activities of Hydroflumethiazide.	Approved
Hydromorphone	The metabolism of Hydromorphone can be decreased when combined with Venlafaxine.	Approved, Illicit
Hydroxyprogesterone caproate	The metabolism of Hydroxyprogesterone caproate can be decreased when combined with Venlafaxine.	Approved
Hydroxyzine	The risk or severity of adverse effects can be increased when Hydroxyzine is combined with Venlafaxine.	Approved
Ibrutinib	The serum concentration of Ibrutinib can be increased when it is combined with Venlafaxine.	Approved
Ibuprofen	The serum concentration of Ibuprofen can be increased when it is combined with Venlafaxine.	Approved
Ibutilide	Venlafaxine may increase the QTc-prolonging activities of Ibutilide.	Approved
Icotinib	The metabolism of Icotinib can be decreased when combined with Venlafaxine.	Approved, Investigational
Idarubicin	The metabolism of Idarubicin can be decreased when combined with Venlafaxine.	Approved
Idelalisib	The serum concentration of Venlafaxine can be increased when it is combined with Idelalisib.	Approved
Ifosfamide	The serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Venlafaxine resulting in a loss in efficacy.	Approved
Iloperidone	Venlafaxine may increase the QTc-prolonging activities of Iloperidone.	Approved
Imatinib	The serum concentration of Imatinib can be increased when it is combined with Venlafaxine.	Approved
Imidafenacin	The metabolism of Imidafenacin can be decreased when combined with Venlafaxine.	Approved
Imipramine	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Imipramine.	Approved
Imiquimod	The metabolism of Imiquimod can be decreased when combined with Venlafaxine.	Approved, Investigational
Indacaterol	The metabolism of Indacaterol can be decreased when combined with Venlafaxine.	Approved
Indalpine	Venlafaxine may increase the serotonergic activities of Indalpine.	Investigational, Withdrawn
Indapamide	The metabolism of Indapamide can be decreased when combined with Venlafaxine.	Approved
Indenolol	The serum concentration of Indenolol can be increased when it is combined with Venlafaxine.	Withdrawn
Indinavir	The serum concentration of Indinavir can be decreased when it is combined with Venlafaxine.	Approved
Indiplon	The risk or severity of adverse effects can be increased when Indiplon is combined with Venlafaxine.	Investigational
Indomethacin	The serum concentration of Venlafaxine can be increased when it is combined with Indomethacin.	Approved, Investigational
Inotuzumab ozogamicin	The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Venlafaxine.	Approved
Insulin Aspart	Venlafaxine may increase the hypoglycemic activities of Insulin Aspart.	Approved
Insulin Detemir	Venlafaxine may increase the hypoglycemic activities of Insulin Detemir.	Approved
Insulin Glargine	Venlafaxine may increase the hypoglycemic activities of Insulin Glargine.	Approved
Insulin Glulisine	Venlafaxine may increase the hypoglycemic activities of Insulin Glulisine.	Approved
Insulin Human	Venlafaxine may increase the hypoglycemic activities of Insulin Human.	Approved, Investigational
Insulin Lispro	Venlafaxine may increase the hypoglycemic activities of Insulin Lispro.	Approved
Iobenguane	The therapeutic efficacy of Iobenguane can be decreased when used in combination with Venlafaxine.	Approved
Ioflupane I-123	Venlafaxine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.	Approved
Ipratropium bromide	The metabolism of Ipratropium bromide can be decreased when combined with Venlafaxine.	Approved
Iproclozide	Iproclozide may increase the serotonergic activities of Venlafaxine.	Withdrawn
Iproniazid	Iproniazid may increase the serotonergic activities of Venlafaxine.	Withdrawn
Irbesartan	The metabolism of Venlafaxine can be decreased when combined with Irbesartan.	Approved, Investigational
Irinotecan	The metabolism of Irinotecan can be decreased when combined with Venlafaxine.	Approved, Investigational
Isavuconazonium	The metabolism of Isavuconazonium can be decreased when combined with Venlafaxine.	Approved, Investigational
Isocarboxazid	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Isocarboxazid.	Approved
Isoetarine	Venlafaxine may increase the tachycardic activities of Isoetarine.	Approved
Isoflurane	The metabolism of Isoflurane can be decreased when combined with Venlafaxine.	Approved, Vet Approved
Isoniazid	The metabolism of Venlafaxine can be decreased when combined with Isoniazid.	Approved
Isoprenaline	Venlafaxine may increase the tachycardic activities of Isoprenaline.	Approved
Isosorbide Dinitrate	The metabolism of Isosorbide Dinitrate can be decreased when combined with Venlafaxine.	Approved
Isosorbide Mononitrate	The metabolism of Isosorbide Mononitrate can be decreased when combined with Venlafaxine.	Approved
Isoxsuprine	Venlafaxine may increase the tachycardic activities of Isoxsuprine.	Approved, Withdrawn
Isradipine	The metabolism of Venlafaxine can be decreased when combined with Isradipine.	Approved
Itraconazole	The metabolism of Venlafaxine can be decreased when combined with Itraconazole.	Approved, Investigational
Ivabradine	The serum concentration of Ivabradine can be increased when it is combined with Venlafaxine.	Approved
Ivacaftor	The serum concentration of Ivacaftor can be increased when it is combined with Venlafaxine.	Approved
Ivermectin	The metabolism of Ivermectin can be decreased when combined with Venlafaxine.	Approved, Vet Approved
Ixabepilone	The metabolism of Ixabepilone can be decreased when combined with Venlafaxine.	Approved, Investigational
Ixazomib	The metabolism of Ixazomib can be decreased when combined with Venlafaxine.	Approved
Ketamine	The metabolism of Ketamine can be decreased when combined with Venlafaxine.	Approved, Vet Approved
Ketazolam	The metabolism of Ketazolam can be decreased when combined with Venlafaxine.	Approved
Ketobemidone	The metabolism of Ketobemidone can be decreased when combined with Venlafaxine.	Approved
Ketoconazole	The metabolism of Venlafaxine can be decreased when combined with Ketoconazole.	Approved, Investigational
L-Tryptophan	L-Tryptophan may increase the serotonergic activities of Venlafaxine.	Approved, Nutraceutical, Withdrawn
Labetalol	The metabolism of Labetalol can be decreased when combined with Venlafaxine.	Approved
Lamivudine	The serum concentration of Lamivudine can be increased when it is combined with Venlafaxine.	Approved, Investigational
Lamotrigine	The serum concentration of Lamotrigine can be increased when it is combined with Venlafaxine.	Approved, Investigational
Landiolol	The serum concentration of Landiolol can be increased when it is combined with Venlafaxine.	Investigational
Lansoprazole	The metabolism of Lansoprazole can be decreased when combined with Venlafaxine.	Approved, Investigational
Lapatinib	The metabolism of Lapatinib can be decreased when combined with Venlafaxine.	Approved, Investigational
Laquinimod	The metabolism of Laquinimod can be decreased when combined with Venlafaxine.	Investigational
Ledipasvir	The serum concentration of Ledipasvir can be increased when it is combined with Venlafaxine.	Approved
Leflunomide	The metabolism of Venlafaxine can be decreased when combined with Leflunomide.	Approved, Investigational
Lenalidomide	The serum concentration of Lenalidomide can be increased when it is combined with Venlafaxine.	Approved
Lenvatinib	Venlafaxine may increase the QTc-prolonging activities of Lenvatinib.	Approved
Lercanidipine	The metabolism of Lercanidipine can be decreased when combined with Venlafaxine.	Approved, Investigational
Letrozole	The metabolism of Letrozole can be decreased when combined with Venlafaxine.	Approved, Investigational
Leuprolide	Venlafaxine may increase the QTc-prolonging activities of Leuprolide.	Approved, Investigational
Levetiracetam	The serum concentration of Levetiracetam can be increased when it is combined with Venlafaxine.	Approved, Investigational
Levobunolol	The serum concentration of Levobunolol can be increased when it is combined with Venlafaxine.	Approved
Levobupivacaine	The metabolism of Levobupivacaine can be decreased when combined with Venlafaxine.	Approved
Levocabastine	The risk or severity of adverse effects can be increased when Levocabastine is combined with Venlafaxine.	Approved
Levocetirizine	The metabolism of Levocetirizine can be decreased when combined with Venlafaxine.	Approved
Levodopa	The metabolism of Levodopa can be decreased when combined with Venlafaxine.	Approved
Levofloxacin	Venlafaxine may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational
Levomethadyl Acetate	The metabolism of Levomethadyl Acetate can be decreased when combined with Venlafaxine.	Approved
Levomilnacipran	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Levomilnacipran.	Approved
Levonordefrin	Venlafaxine may decrease the antihypertensive activities of Levonordefrin.	Approved
Levonorgestrel	The metabolism of Levonorgestrel can be decreased when combined with Venlafaxine.	Approved, Investigational
Levorphanol	Levorphanol may increase the serotonergic activities of Venlafaxine.	Approved
Levothyroxine	The metabolism of Levothyroxine can be decreased when combined with Venlafaxine.	Approved
Lidocaine	The metabolism of Lidocaine can be decreased when combined with Venlafaxine.	Approved, Vet Approved
Linagliptin	The serum concentration of Linagliptin can be increased when it is combined with Venlafaxine.	Approved
Linezolid	Linezolid may increase the serotonergic activities of Venlafaxine.	Approved, Investigational
Liothyronine	The serum concentration of Venlafaxine can be decreased when it is combined with Liothyronine.	Approved, Vet Approved
Liotrix	The serum concentration of Venlafaxine can be decreased when it is combined with Liotrix.	Approved
Liraglutide	Venlafaxine may increase the hypoglycemic activities of Liraglutide.	Approved
Lisinopril	The serum concentration of Venlafaxine can be increased when it is combined with Lisinopril.	Approved, Investigational
Lisuride	The metabolism of Lisuride can be decreased when combined with Venlafaxine.	Approved
Lithium	Lithium may increase the serotonergic activities of Venlafaxine.	Approved
Lobeglitazone	The metabolism of Venlafaxine can be decreased when combined with Lobeglitazone.	Approved
Lofentanil	Lofentanil may increase the serotonergic activities of Venlafaxine.	Illicit
Lofexidine	Venlafaxine may increase the tachycardic activities of Lofexidine.	Approved, Investigational
Lomitapide	The serum concentration of Lomitapide can be increased when it is combined with Venlafaxine.	Approved
Lomustine	The metabolism of Lomustine can be decreased when combined with Venlafaxine.	Approved
Loperamide	The metabolism of Loperamide can be decreased when combined with Venlafaxine.	Approved
Lopinavir	The metabolism of Venlafaxine can be decreased when combined with Lopinavir.	Approved
Loprazolam	The risk or severity of adverse effects can be increased when Loprazolam is combined with Venlafaxine.	Experimental
Loratadine	The metabolism of Loratadine can be decreased when combined with Venlafaxine.	Approved
Lorazepam	The risk or severity of adverse effects can be increased when Lorazepam is combined with Venlafaxine.	Approved
Lorcaserin	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Lorcaserin.	Approved
Lormetazepam	The risk or severity of adverse effects can be increased when Lormetazepam is combined with Venlafaxine.	Approved
Losartan	The metabolism of Losartan can be decreased when combined with Venlafaxine.	Approved
Lovastatin	The metabolism of Venlafaxine can be decreased when combined with Lovastatin.	Approved, Investigational
Loxapine	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Loxapine.	Approved
Luliconazole	The serum concentration of Venlafaxine can be increased when it is combined with Luliconazole.	Approved
Lumacaftor	The serum concentration of Venlafaxine can be decreased when it is combined with Lumacaftor.	Approved
Lumefantrine	Venlafaxine may increase the QTc-prolonging activities of Lumefantrine.	Approved
Lumiracoxib	Venlafaxine may increase the antiplatelet activities of Lumiracoxib.	Approved, Investigational
Lurasidone	The serum concentration of Lurasidone can be increased when it is combined with Venlafaxine.	Approved
Lysergic Acid Diethylamide	The risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Venlafaxine.	Illicit, Withdrawn
Macitentan	The metabolism of Macitentan can be decreased when combined with Venlafaxine.	Approved
Magnesium Sulfate	The risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Venlafaxine.	Approved, Vet Approved
Malathion	The metabolism of Malathion can be decreased when combined with Venlafaxine.	Approved, Investigational
Manidipine	The metabolism of Venlafaxine can be decreased when combined with Manidipine.	Approved
Mannitol	The serum concentration of Mannitol can be increased when it is combined with Venlafaxine.	Approved, Investigational
Maprotiline	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Maprotiline.	Approved
Maraviroc	The metabolism of Maraviroc can be decreased when combined with Venlafaxine.	Approved, Investigational
Mebanazine	Mebanazine may increase the serotonergic activities of Venlafaxine.	Withdrawn
Mebendazole	The metabolism of Mebendazole can be decreased when combined with Venlafaxine.	Approved, Vet Approved
Mebicar	The risk or severity of adverse effects can be increased when Mebicar is combined with Venlafaxine.	Experimental
Mecasermin	Venlafaxine may increase the hypoglycemic activities of Mecasermin.	Approved, Investigational
Meclizine	The risk or severity of adverse effects can be increased when Meclizine is combined with Venlafaxine.	Approved
Medazepam	The risk or severity of adverse effects can be increased when Medazepam is combined with Venlafaxine.	Experimental
Medetomidine	Venlafaxine may increase the tachycardic activities of Medetomidine.	Vet Approved
Medroxyprogesterone acetate	The metabolism of Medroxyprogesterone acetate can be decreased when combined with Venlafaxine.	Approved, Investigational
Mefloquine	The metabolism of Mefloquine can be decreased when combined with Venlafaxine.	Approved
Megestrol acetate	The serum concentration of Venlafaxine can be increased when it is combined with Megestrol acetate.	Approved, Vet Approved
Melatonin	The risk or severity of adverse effects can be increased when Melatonin is combined with Venlafaxine.	Approved, Nutraceutical, Vet Approved
Meloxicam	The metabolism of Meloxicam can be decreased when combined with Venlafaxine.	Approved, Vet Approved
Melperone	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Melperone.	Approved
Mephentermine	Venlafaxine may increase the tachycardic activities of Mephentermine.	Approved
Mephenytoin	The metabolism of Mephenytoin can be decreased when combined with Venlafaxine.	Investigational, Withdrawn
Mepindolol	The serum concentration of Mepindolol can be increased when it is combined with Venlafaxine.	Experimental
Mepivacaine	The risk or severity of adverse effects can be increased when Mepivacaine is combined with Venlafaxine.	Approved, Vet Approved
Meprobamate	The serum concentration of Venlafaxine can be increased when it is combined with Meprobamate.	Approved, Illicit
Meptazinol	Meptazinol may increase the serotonergic activities of Venlafaxine.	Experimental
Mequitazine	The metabolism of Mequitazine can be decreased when combined with Venlafaxine.	Approved
Mesoridazine	The metabolism of Mesoridazine can be decreased when combined with Venlafaxine.	Approved
Metaraminol	Venlafaxine may increase the tachycardic activities of Metaraminol.	Approved, Investigational
Metaxalone	The risk or severity of adverse effects can be increased when Metaxalone is combined with Venlafaxine.	Approved
Metergoline	The risk or severity of adverse effects can be increased when Metergoline is combined with Venlafaxine.	Experimental
Metformin	Venlafaxine may increase the hypoglycemic activities of Metformin.	Approved
Methadone	The metabolism of Methadone can be decreased when combined with Venlafaxine.	Approved
Methadyl Acetate	Methadyl Acetate may increase the serotonergic activities of Venlafaxine.	Approved, Illicit
Methamphetamine	The metabolism of Methamphetamine can be decreased when combined with Venlafaxine.	Approved, Illicit
Methapyrilene	The risk or severity of adverse effects can be increased when Methapyrilene is combined with Venlafaxine.	Withdrawn
Methaqualone	The metabolism of Methaqualone can be decreased when combined with Venlafaxine.	Illicit, Withdrawn
Methocarbamol	The risk or severity of adverse effects can be increased when Methocarbamol is combined with Venlafaxine.	Approved, Vet Approved
Methohexital	The risk or severity of adverse effects can be increased when Methohexital is combined with Venlafaxine.	Approved
Methotrexate	The serum concentration of Methotrexate can be increased when it is combined with Venlafaxine.	Approved
Methotrimeprazine	The metabolism of Venlafaxine can be decreased when combined with Methotrimeprazine.	Approved
Methoxamine	Venlafaxine may increase the tachycardic activities of Methoxamine.	Approved
Methoxsalen	The metabolism of Methoxsalen can be decreased when combined with Venlafaxine.	Approved
Methoxyflurane	The metabolism of Methoxyflurane can be decreased when combined with Venlafaxine.	Approved, Vet Approved
Methoxyphenamine	Venlafaxine may increase the tachycardic activities of Methoxyphenamine.	Experimental
Methsuximide	The risk or severity of adverse effects can be increased when Methsuximide is combined with Venlafaxine.	Approved
Methyclothiazide	Venlafaxine may increase the hyponatremic activities of Methyclothiazide.	Approved
Methyl salicylate	The metabolism of Methyl salicylate can be decreased when combined with Venlafaxine.	Approved, Vet Approved
Methyldopa	Venlafaxine may increase the tachycardic activities of Methyldopa.	Approved
Methylecgonine	The risk or severity of adverse effects can be increased when Methylecgonine is combined with Venlafaxine.	Experimental
Methylene blue	Venlafaxine may increase the serotonergic activities of Methylene blue.	Investigational
Methylergometrine	The risk or severity of adverse effects can be increased when Methylergometrine is combined with Venlafaxine.	Approved
Methylphenidate	The metabolism of Methylphenidate can be decreased when combined with Venlafaxine.	Approved, Investigational
Methylphenobarbital	The metabolism of Methylphenobarbital can be decreased when combined with Venlafaxine.	Approved
Methylprednisolone	The metabolism of Methylprednisolone can be decreased when combined with Venlafaxine.	Approved, Vet Approved
Methyltestosterone	The metabolism of Methyltestosterone can be decreased when combined with Venlafaxine.	Approved
Methyprylon	The metabolism of Methyprylon can be decreased when combined with Venlafaxine.	Approved, Illicit, Withdrawn
Methysergide	The risk or severity of adverse effects can be increased when Methysergide is combined with Venlafaxine.	Approved
Metipranolol	The serum concentration of Metipranolol can be increased when it is combined with Venlafaxine.	Approved
Metoclopramide	The risk or severity of adverse effects can be increased when Metoclopramide is combined with Venlafaxine.	Approved, Investigational
Metolazone	Venlafaxine may increase the hyponatremic activities of Metolazone.	Approved
Metoprolol	The serum concentration of Metoprolol can be increased when it is combined with Venlafaxine.	Approved, Investigational
Metronidazole	The metabolism of Metronidazole can be decreased when combined with Venlafaxine.	Approved
Metyrosine	The risk or severity of adverse effects can be increased when Metyrosine is combined with Venlafaxine.	Approved
Mevastatin	The serum concentration of Mevastatin can be increased when it is combined with Venlafaxine.	Experimental
Mexiletine	The metabolism of Mexiletine can be decreased when combined with Venlafaxine.	Approved
Mianserin	The metabolism of Mianserin can be decreased when combined with Venlafaxine.	Approved
Mibefradil	The metabolism of Mibefradil can be decreased when combined with Venlafaxine.	Withdrawn
Miconazole	The metabolism of Miconazole can be decreased when combined with Venlafaxine.	Approved, Investigational, Vet Approved
Midazolam	The metabolism of Midazolam can be decreased when combined with Venlafaxine.	Approved, Illicit
Midodrine	Venlafaxine may increase the tachycardic activities of Midodrine.	Approved
Midostaurin	The metabolism of Venlafaxine can be decreased when combined with Midostaurin.	Approved
Mifepristone	The serum concentration of Venlafaxine can be increased when it is combined with Mifepristone.	Approved, Investigational
Miglitol	Venlafaxine may increase the hypoglycemic activities of Miglitol.	Approved
Milnacipran	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Milnacipran.	Approved
Minaprine	The metabolism of Minaprine can be decreased when combined with Venlafaxine.	Approved
Mirabegron	Venlafaxine may increase the tachycardic activities of Mirabegron.	Approved
Mirtazapine	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Mirtazapine.	Approved
Mitomycin	The serum concentration of Venlafaxine can be increased when it is combined with Mitomycin.	Approved
Mitotane	The serum concentration of Venlafaxine can be decreased when it is combined with Mitotane.	Approved
Mitoxantrone	The serum concentration of Venlafaxine can be decreased when it is combined with Mitoxantrone.	Approved, Investigational
Moclobemide	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Moclobemide.	Approved
Modafinil	The metabolism of Modafinil can be decreased when combined with Venlafaxine.	Approved, Investigational
Molindone	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Molindone.	Approved
Montelukast	The metabolism of Montelukast can be decreased when combined with Venlafaxine.	Approved
Moperone	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Moperone.	Experimental
Morphine	The metabolism of Morphine can be decreased when combined with Venlafaxine.	Approved, Investigational
Mosapramine	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Mosapramine.	Experimental
Moxifloxacin	Venlafaxine may increase the QTc-prolonging activities of Moxifloxacin.	Approved, Investigational
Moxonidine	Venlafaxine may decrease the antihypertensive activities of Moxonidine.	Approved
Mycophenolate mofetil	The metabolism of Mycophenolate mofetil can be decreased when combined with Venlafaxine.	Approved, Investigational
Nabilone	The risk or severity of adverse effects can be increased when Nabilone is combined with Venlafaxine.	Approved, Investigational
Nabumetone	Venlafaxine may increase the antiplatelet activities of Nabumetone.	Approved
Nadolol	The serum concentration of Nadolol can be increased when it is combined with Venlafaxine.	Approved
Nalbuphine	Nalbuphine may increase the serotonergic activities of Venlafaxine.	Approved
Naloxone	The metabolism of Naloxone can be decreased when combined with Venlafaxine.	Approved, Vet Approved
Naltrexone	The serum concentration of Venlafaxine can be increased when it is combined with Naltrexone.	Approved, Investigational, Vet Approved
Naphazoline	Venlafaxine may increase the tachycardic activities of Naphazoline.	Approved
Naratriptan	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Naratriptan.	Approved, Investigational
Naringenin	The serum concentration of Venlafaxine can be increased when it is combined with Naringenin.	Experimental
Nateglinide	The metabolism of Nateglinide can be decreased when combined with Venlafaxine.	Approved, Investigational
Nebivolol	The serum concentration of Nebivolol can be increased when it is combined with Venlafaxine.	Approved, Investigational
Nefazodone	The metabolism of Venlafaxine can be decreased when combined with Nefazodone.	Approved, Withdrawn
Nelfinavir	The metabolism of Venlafaxine can be decreased when combined with Nelfinavir.	Approved
Neostigmine	The serum concentration of Venlafaxine can be increased when it is combined with Neostigmine.	Approved, Vet Approved
Neratinib	The metabolism of Neratinib can be decreased when combined with Venlafaxine.	Approved, Investigational
Netupitant	The serum concentration of Venlafaxine can be increased when it is combined with Netupitant.	Approved
Nevirapine	The metabolism of Venlafaxine can be increased when combined with Nevirapine.	Approved
Nialamide	Nialamide may increase the serotonergic activities of Venlafaxine.	Withdrawn
Nicardipine	The metabolism of Venlafaxine can be decreased when combined with Nicardipine.	Approved
Nicergoline	The metabolism of Nicergoline can be decreased when combined with Venlafaxine.	Approved
Nicomorphine	Nicomorphine may increase the serotonergic activities of Venlafaxine.	Experimental
Nicotine	The metabolism of Nicotine can be decreased when combined with Venlafaxine.	Approved
Nifedipine	The metabolism of Nifedipine can be decreased when combined with Venlafaxine.	Approved
Nilotinib	Venlafaxine may increase the QTc-prolonging activities of Nilotinib.	Approved, Investigational
Nilvadipine	The metabolism of Nilvadipine can be decreased when combined with Venlafaxine.	Approved
Nimodipine	The serum concentration of Nimodipine can be increased when it is combined with Venlafaxine.	Approved
Nintedanib	The serum concentration of Nintedanib can be increased when it is combined with Venlafaxine.	Approved
Nisoldipine	The metabolism of Nisoldipine can be decreased when combined with Venlafaxine.	Approved
Nitrazepam	The metabolism of Nitrazepam can be decreased when combined with Venlafaxine.	Approved
Nitrendipine	The metabolism of Nitrendipine can be decreased when combined with Venlafaxine.	Approved
Nitrofural	The metabolism of Nitrofural can be decreased when combined with Venlafaxine.	Approved, Vet Approved
Nitrous oxide	The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Venlafaxine.	Approved, Vet Approved
Nizatidine	The serum concentration of Nizatidine can be increased when it is combined with Venlafaxine.	Approved
Norepinephrine	Venlafaxine may increase the tachycardic activities of Norepinephrine.	Approved
Norethisterone	The metabolism of Norethisterone can be decreased when combined with Venlafaxine.	Approved
Norfenefrine	Venlafaxine may increase the tachycardic activities of Norfenefrine.	Experimental
Norflurane	The risk or severity of adverse effects can be increased when Norflurane is combined with Venlafaxine.	Investigational
Norgestrel	The metabolism of Norgestrel can be decreased when combined with Venlafaxine.	Approved
Normethadone	Normethadone may increase the serotonergic activities of Venlafaxine.	Approved, Illicit
Nortriptyline	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Nortriptyline.	Approved
Nylidrin	Venlafaxine may increase the tachycardic activities of Nylidrin.	Approved
Octamoxin	Octamoxin may increase the serotonergic activities of Venlafaxine.	Withdrawn
Octopamine	Venlafaxine may increase the tachycardic activities of Octopamine.	Experimental
Odanacatib	The metabolism of Odanacatib can be decreased when combined with Venlafaxine.	Investigational
Ofloxacin	Venlafaxine may increase the QTc-prolonging activities of Ofloxacin.	Approved
Olanzapine	Venlafaxine may increase the serotonergic activities of Olanzapine.	Approved, Investigational
Olaparib	The serum concentration of Olaparib can be increased when it is combined with Venlafaxine.	Approved
Olodaterol	Venlafaxine may increase the tachycardic activities of Olodaterol.	Approved
Olopatadine	The metabolism of Olopatadine can be decreased when combined with Venlafaxine.	Approved
Ombitasvir	The serum concentration of Ombitasvir can be increased when it is combined with Venlafaxine.	Approved
Omeprazole	The metabolism of Omeprazole can be decreased when combined with Venlafaxine.	Approved, Investigational, Vet Approved
Ondansetron	Venlafaxine may increase the QTc-prolonging activities of Ondansetron.	Approved
Opium	Opium may increase the serotonergic activities of Venlafaxine.	Approved, Illicit
Orciprenaline	Venlafaxine may increase the tachycardic activities of Orciprenaline.	Approved
Orphenadrine	The metabolism of Orphenadrine can be decreased when combined with Venlafaxine.	Approved
Osanetant	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Osanetant.	Investigational
Osimertinib	The serum concentration of Venlafaxine can be increased when it is combined with Osimertinib.	Approved
Ospemifene	The metabolism of Ospemifene can be decreased when combined with Venlafaxine.	Approved
Oxazepam	The metabolism of Oxazepam can be decreased when combined with Venlafaxine.	Approved
Oxethazaine	The risk or severity of adverse effects can be increased when Oxethazaine is combined with Venlafaxine.	Investigational
Oxprenolol	The serum concentration of Oxprenolol can be increased when it is combined with Venlafaxine.	Approved
Oxybuprocaine	The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Venlafaxine.	Approved
Oxybutynin	The metabolism of Oxybutynin can be decreased when combined with Venlafaxine.	Approved, Investigational
Oxycodone	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Oxycodone.	Approved, Illicit, Investigational
Oxyfedrine	Venlafaxine may increase the tachycardic activities of Oxyfedrine.	Experimental
Oxymetazoline	Venlafaxine may increase the tachycardic activities of Oxymetazoline.	Approved
Oxymorphone	The metabolism of Oxymorphone can be decreased when combined with Venlafaxine.	Approved, Investigational, Vet Approved
Oxypertine	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Oxypertine.	Experimental
P-Nitrophenol	The serum concentration of Venlafaxine can be increased when it is combined with P-Nitrophenol.	Experimental
Paclitaxel	The metabolism of Paclitaxel can be decreased when combined with Venlafaxine.	Approved, Vet Approved
Palbociclib	The serum concentration of Venlafaxine can be increased when it is combined with Palbociclib.	Approved
Paliperidone	Venlafaxine may increase the QTc-prolonging activities of Paliperidone.	Approved
Palmitic Acid	The serum concentration of Venlafaxine can be increased when it is combined with Palmitic Acid.	Experimental
Palonosetron	The metabolism of Palonosetron can be decreased when combined with Venlafaxine.	Approved, Investigational
Panobinostat	The serum concentration of Venlafaxine can be increased when it is combined with Panobinostat.	Approved, Investigational
Pantoprazole	The metabolism of Pantoprazole can be decreased when combined with Venlafaxine.	Approved
Paraldehyde	The risk or severity of adverse effects can be increased when Paraldehyde is combined with Venlafaxine.	Approved
Paramethadione	The metabolism of Paramethadione can be decreased when combined with Venlafaxine.	Approved
Paramethasone	The metabolism of Paramethasone can be decreased when combined with Venlafaxine.	Approved
Parecoxib	Venlafaxine may increase the antiplatelet activities of Parecoxib.	Approved
Pargyline	Pargyline may increase the serotonergic activities of Venlafaxine.	Approved
Paricalcitol	The metabolism of Paricalcitol can be decreased when combined with Venlafaxine.	Approved, Investigational
Paritaprevir	The metabolism of Paritaprevir can be decreased when combined with Venlafaxine.	Approved
Paroxetine	The metabolism of Venlafaxine can be decreased when combined with Paroxetine.	Approved, Investigational
Pazopanib	The serum concentration of Pazopanib can be increased when it is combined with Venlafaxine.	Approved
Peginterferon alfa-2b	The serum concentration of Venlafaxine can be decreased when it is combined with Peginterferon alfa-2b.	Approved
Penbutolol	The serum concentration of Penbutolol can be increased when it is combined with Venlafaxine.	Approved, Investigational
Penfluridol	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Penfluridol.	Experimental
Pentamidine	Venlafaxine may increase the QTc-prolonging activities of Pentamidine.	Approved
Pentazocine	Pentazocine may increase the serotonergic activities of Venlafaxine.	Approved, Vet Approved
Pentobarbital	The metabolism of Venlafaxine can be increased when combined with Pentobarbital.	Approved, Vet Approved
Perampanel	The metabolism of Perampanel can be decreased when combined with Venlafaxine.	Approved
Perazine	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Perazine.	Investigational
Perflutren	Venlafaxine may increase the QTc-prolonging activities of Perflutren.	Approved
Pergolide	The metabolism of Pergolide can be decreased when combined with Venlafaxine.	Approved, Vet Approved, Withdrawn
Perhexiline	The metabolism of Perhexiline can be decreased when combined with Venlafaxine.	Approved
Perindopril	The serum concentration of Venlafaxine can be increased when it is combined with Perindopril.	Approved
Permethrin	The metabolism of Permethrin can be decreased when combined with Venlafaxine.	Approved, Investigational
Perospirone	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Perospirone.	Approved
Perphenazine	The metabolism of Perphenazine can be decreased when combined with Venlafaxine.	Approved
Pethidine	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Pethidine.	Approved
Phenacetin	The metabolism of Phenacetin can be decreased when combined with Venlafaxine.	Withdrawn
Phenazocine	Phenazocine may increase the serotonergic activities of Venlafaxine.	Experimental
Phenelzine	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Phenelzine.	Approved
Phenformin	The metabolism of Phenformin can be decreased when combined with Venlafaxine.	Approved, Withdrawn
Phenibut	The risk or severity of adverse effects can be increased when Phenibut is combined with Venlafaxine.	Experimental
Phenindione	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Phenindione.	Approved
Pheniprazine	Pheniprazine may increase the serotonergic activities of Venlafaxine.	Withdrawn
Phenobarbital	The metabolism of Venlafaxine can be increased when combined with Phenobarbital.	Approved
Phenoperidine	Phenoperidine may increase the serotonergic activities of Venlafaxine.	Experimental
Phenoxybenzamine	The metabolism of Phenoxybenzamine can be decreased when combined with Venlafaxine.	Approved
Phenoxyethanol	The risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Venlafaxine.	Approved
Phenoxypropazine	Phenoxypropazine may increase the serotonergic activities of Venlafaxine.	Withdrawn
Phenprocoumon	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Phenprocoumon.	Approved
Phenylephrine	Venlafaxine may increase the tachycardic activities of Phenylephrine.	Approved
Phenylpropanolamine	Venlafaxine may increase the tachycardic activities of Phenylpropanolamine.	Approved, Vet Approved, Withdrawn
Phenytoin	The metabolism of Venlafaxine can be increased when combined with Phenytoin.	Approved, Vet Approved
Pibrentasvir	The serum concentration of Pibrentasvir can be increased when it is combined with Venlafaxine.	Approved
Pilocarpine	The metabolism of Pilocarpine can be decreased when combined with Venlafaxine.	Approved
Pimecrolimus	The metabolism of Pimecrolimus can be decreased when combined with Venlafaxine.	Approved, Investigational
Pimozide	The serum concentration of Pimozide can be increased when it is combined with Venlafaxine.	Approved
Pinacidil	The metabolism of Pinacidil can be decreased when combined with Venlafaxine.	Withdrawn
Pindolol	The metabolism of Pindolol can be decreased when combined with Venlafaxine.	Approved
Pioglitazone	The metabolism of Pioglitazone can be decreased when combined with Venlafaxine.	Approved, Investigational
Pipamperone	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Pipamperone.	Approved
Piperazine	The metabolism of Piperazine can be decreased when combined with Venlafaxine.	Approved, Vet Approved
Pipotiazine	The metabolism of Pipotiazine can be decreased when combined with Venlafaxine.	Approved
Pirbuterol	Venlafaxine may increase the tachycardic activities of Pirbuterol.	Approved
Piritramide	Piritramide may increase the serotonergic activities of Venlafaxine.	Investigational
Pirlindole	Pirlindole may increase the serotonergic activities of Venlafaxine.	Approved
Pitavastatin	The serum concentration of Pitavastatin can be increased when it is combined with Venlafaxine.	Approved
Pivhydrazine	Pivhydrazine may increase the serotonergic activities of Venlafaxine.	Withdrawn
Pizotifen	The risk or severity of adverse effects can be increased when Pizotifen is combined with Venlafaxine.	Approved
Platelet Activating Factor	The serum concentration of Venlafaxine can be decreased when it is combined with Platelet Activating Factor.	Experimental
Podofilox	The metabolism of Podofilox can be decreased when combined with Venlafaxine.	Approved
Polythiazide	Venlafaxine may increase the hyponatremic activities of Polythiazide.	Approved
Pomalidomide	The metabolism of Pomalidomide can be decreased when combined with Venlafaxine.	Approved
Ponatinib	The metabolism of Ponatinib can be decreased when combined with Venlafaxine.	Approved
Posaconazole	The metabolism of Venlafaxine can be decreased when combined with Posaconazole.	Approved, Investigational, Vet Approved
Practolol	The serum concentration of Practolol can be increased when it is combined with Venlafaxine.	Approved
Pramlintide	Venlafaxine may increase the hypoglycemic activities of Pramlintide.	Approved, Investigational
Pramocaine	The risk or severity of adverse effects can be increased when Pramocaine is combined with Venlafaxine.	Approved
Prasterone	The metabolism of Prasterone can be decreased when combined with Venlafaxine.	Approved, Nutraceutical
Prasugrel	The metabolism of Prasugrel can be decreased when combined with Venlafaxine.	Approved
Pravastatin	The metabolism of Pravastatin can be decreased when combined with Venlafaxine.	Approved
Prazepam	The metabolism of Prazepam can be decreased when combined with Venlafaxine.	Approved, Illicit
Praziquantel	The metabolism of Praziquantel can be decreased when combined with Venlafaxine.	Approved, Vet Approved
Prazosin	The serum concentration of Venlafaxine can be increased when it is combined with Prazosin.	Approved
Prednisolone	The metabolism of Prednisolone can be decreased when combined with Venlafaxine.	Approved, Vet Approved
Prednisone	The metabolism of Prednisone can be decreased when combined with Venlafaxine.	Approved, Vet Approved
Pregabalin	The risk or severity of adverse effects can be increased when Pregabalin is combined with Venlafaxine.	Approved, Illicit, Investigational
Prenalterol	Venlafaxine may increase the tachycardic activities of Prenalterol.	Experimental
Prilocaine	The risk or severity of adverse effects can be increased when Prilocaine is combined with Venlafaxine.	Approved
Primaquine	Venlafaxine may increase the QTc-prolonging activities of Primaquine.	Approved
Primidone	The metabolism of Venlafaxine can be increased when combined with Primidone.	Approved, Vet Approved
Probenecid	The serum concentration of Venlafaxine can be increased when it is combined with Probenecid.	Approved
Procainamide	Venlafaxine may increase the QTc-prolonging activities of Procainamide.	Approved
Procaine	The risk or severity of adverse effects can be increased when Procaine is combined with Venlafaxine.	Approved, Investigational, Vet Approved
Procarbazine	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Procarbazine.	Approved
Procaterol	Venlafaxine may increase the tachycardic activities of Procaterol.	Approved
Prochlorperazine	The metabolism of Prochlorperazine can be decreased when combined with Venlafaxine.	Approved, Vet Approved
Progesterone	The metabolism of Progesterone can be decreased when combined with Venlafaxine.	Approved, Vet Approved
Proguanil	The metabolism of Proguanil can be decreased when combined with Venlafaxine.	Approved
Promazine	Venlafaxine may increase the QTc-prolonging activities of Promazine.	Approved, Vet Approved
Promethazine	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Promethazine.	Approved
Propafenone	The serum concentration of Venlafaxine can be increased when it is combined with Propafenone.	Approved
Propanidid	The risk or severity of adverse effects can be increased when Propanidid is combined with Venlafaxine.	Experimental
Proparacaine	The risk or severity of adverse effects can be increased when Proparacaine is combined with Venlafaxine.	Approved, Vet Approved
Propericiazine	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Propericiazine.	Approved
Propofol	The metabolism of Propofol can be decreased when combined with Venlafaxine.	Approved, Investigational, Vet Approved
Propoxycaine	The risk or severity of adverse effects can be increased when Propoxycaine is combined with Venlafaxine.	Approved
Propoxyphene napsylate	The metabolism of Propoxyphene napsylate can be decreased when combined with Venlafaxine.	Approved
Propranolol	The metabolism of Propranolol can be decreased when combined with Venlafaxine.	Approved, Investigational
Prothipendyl	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Prothipendyl.	Investigational
Protriptyline	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Protriptyline.	Approved
Proxibarbal	The risk or severity of adverse effects can be increased when Proxibarbal is combined with Venlafaxine.	Experimental
Prucalopride	The serum concentration of Prucalopride can be increased when it is combined with Venlafaxine.	Approved
PSD502	The risk or severity of adverse effects can be increased when PSD502 is combined with Venlafaxine.	Investigational
Pseudoephedrine	Venlafaxine may increase the tachycardic activities of Pseudoephedrine.	Approved
Pyrazinamide	The metabolism of Pyrazinamide can be decreased when combined with Venlafaxine.	Approved
Pyrimethamine	The metabolism of Venlafaxine can be decreased when combined with Pyrimethamine.	Approved, Vet Approved
Quazepam	The metabolism of Quazepam can be decreased when combined with Venlafaxine.	Approved, Illicit
Quercetin	The serum concentration of Venlafaxine can be increased when it is combined with Quercetin.	Experimental
Quetiapine	Venlafaxine may increase the QTc-prolonging activities of Quetiapine.	Approved
Quinacrine	The metabolism of Quinacrine can be decreased when combined with Venlafaxine.	Approved
Quinethazone	Venlafaxine may increase the hyponatremic activities of Quinethazone.	Approved
Quinidine	Venlafaxine may increase the QTc-prolonging activities of Quinidine.	Approved
Quinine	Venlafaxine may increase the QTc-prolonging activities of Quinine.	Approved
Quinisocaine	The risk or severity of adverse effects can be increased when Quinisocaine is combined with Venlafaxine.	Experimental
Rabeprazole	The metabolism of Rabeprazole can be decreased when combined with Venlafaxine.	Approved, Investigational
Racepinephrine	Venlafaxine may increase the tachycardic activities of Racepinephrine.	Approved
Raclopride	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Raclopride.	Investigational
Ractopamine	Venlafaxine may increase the tachycardic activities of Ractopamine.	Vet Approved
Raloxifene	The metabolism of Raloxifene can be decreased when combined with Venlafaxine.	Approved, Investigational
Ramelteon	The metabolism of Ramelteon can be decreased when combined with Venlafaxine.	Approved, Investigational
Ranitidine	The serum concentration of Venlafaxine can be increased when it is combined with Ranitidine.	Approved
Ranolazine	The serum concentration of Ranolazine can be increased when it is combined with Venlafaxine.	Approved, Investigational
Rasagiline	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Rasagiline.	Approved
Reboxetine	The metabolism of Reboxetine can be decreased when combined with Venlafaxine.	Approved, Investigational
Regorafenib	The metabolism of Regorafenib can be decreased when combined with Venlafaxine.	Approved
Remifentanil	Remifentanil may increase the serotonergic activities of Venlafaxine.	Approved
Remoxipride	The metabolism of Remoxipride can be decreased when combined with Venlafaxine.	Approved, Withdrawn
Repaglinide	The metabolism of Repaglinide can be decreased when combined with Venlafaxine.	Approved, Investigational
repinotan	The metabolism of repinotan can be decreased when combined with Venlafaxine.	Investigational
Reproterol	Venlafaxine may increase the tachycardic activities of Reproterol.	Investigational
Reserpine	The serum concentration of Venlafaxine can be decreased when it is combined with Reserpine.	Approved
Retapamulin	The metabolism of Retapamulin can be decreased when combined with Venlafaxine.	Approved
Rifabutin	The metabolism of Venlafaxine can be increased when combined with Rifabutin.	Approved
Rifampicin	The metabolism of Venlafaxine can be increased when combined with Rifampicin.	Approved
Rifapentine	The metabolism of Venlafaxine can be increased when combined with Rifapentine.	Approved
Rifaximin	The serum concentration of Rifaximin can be increased when it is combined with Venlafaxine.	Approved, Investigational
Rilmenidine	Venlafaxine may increase the tachycardic activities of Rilmenidine.	Investigational
Rilpivirine	The metabolism of Rilpivirine can be decreased when combined with Venlafaxine.	Approved
Rimiterol	Venlafaxine may increase the tachycardic activities of Rimiterol.	Experimental
Rimonabant	The metabolism of Rimonabant can be decreased when combined with Venlafaxine.	Approved, Investigational
Riociguat	The metabolism of Riociguat can be decreased when combined with Venlafaxine.	Approved
Risperidone	The metabolism of Risperidone can be decreased when combined with Venlafaxine.	Approved, Investigational
Ritanserin	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Ritanserin.	Investigational
Ritobegron	Venlafaxine may increase the tachycardic activities of Ritobegron.	Investigational
Ritodrine	Venlafaxine may increase the tachycardic activities of Ritodrine.	Approved
Ritonavir	The metabolism of Venlafaxine can be decreased when combined with Ritonavir.	Approved, Investigational
Rivaroxaban	The metabolism of Rivaroxaban can be decreased when combined with Venlafaxine.	Approved
Rizatriptan	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Rizatriptan.	Approved
Rofecoxib	Venlafaxine may increase the antiplatelet activities of Rofecoxib.	Investigational, Withdrawn
Rolapitant	The metabolism of Rolapitant can be decreased when combined with Venlafaxine.	Approved
Romidepsin	The metabolism of Romidepsin can be decreased when combined with Venlafaxine.	Approved, Investigational
Romifidine	Venlafaxine may increase the tachycardic activities of Romifidine.	Vet Approved
Ropinirole	The metabolism of Ropinirole can be decreased when combined with Venlafaxine.	Approved, Investigational
Ropivacaine	The metabolism of Ropivacaine can be decreased when combined with Venlafaxine.	Approved
Rosiglitazone	Venlafaxine may increase the hypoglycemic activities of Rosiglitazone.	Approved, Investigational
Rosuvastatin	The metabolism of Rosuvastatin can be decreased when combined with Venlafaxine.	Approved
Rotigotine	The metabolism of Rotigotine can be decreased when combined with Venlafaxine.	Approved
Roxithromycin	The metabolism of Roxithromycin can be decreased when combined with Venlafaxine.	Approved, Withdrawn
Rucaparib	The metabolism of Rucaparib can be decreased when combined with Venlafaxine.	Approved, Investigational
Rupatadine	The metabolism of Rupatadine can be decreased when combined with Venlafaxine.	Approved
Ruxolitinib	The metabolism of Ruxolitinib can be decreased when combined with Venlafaxine.	Approved
Safinamide	The metabolism of Safinamide can be decreased when combined with Venlafaxine.	Approved
Safrazine	Safrazine may increase the serotonergic activities of Venlafaxine.	Withdrawn
Salbutamol	Venlafaxine may increase the tachycardic activities of Salbutamol.	Approved, Vet Approved
Salicylic acid	The serum concentration of Salicylic acid can be increased when it is combined with Venlafaxine.	Approved, Vet Approved
Salmeterol	The serum concentration of Salmeterol can be increased when it is combined with Venlafaxine.	Approved
Saquinavir	The metabolism of Venlafaxine can be decreased when combined with Saquinavir.	Approved, Investigational
Saxagliptin	The serum concentration of Saxagliptin can be increased when it is combined with Venlafaxine.	Approved
Scopolamine	The serum concentration of Venlafaxine can be increased when it is combined with Scopolamine.	Approved
Secobarbital	The metabolism of Venlafaxine can be increased when combined with Secobarbital.	Approved, Vet Approved
Selegiline	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Selegiline.	Approved, Investigational, Vet Approved
Selexipag	The metabolism of Selexipag can be decreased when combined with Venlafaxine.	Approved
Sepranolone	The risk or severity of adverse effects can be increased when Sepranolone is combined with Venlafaxine.	Investigational
Seratrodast	The metabolism of Seratrodast can be decreased when combined with Venlafaxine.	Approved
Sertindole	The metabolism of Sertindole can be decreased when combined with Venlafaxine.	Approved, Withdrawn
Sertraline	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Sertraline.	Approved
Sevoflurane	The metabolism of Sevoflurane can be decreased when combined with Venlafaxine.	Approved, Vet Approved
Sibutramine	The metabolism of Sibutramine can be decreased when combined with Venlafaxine.	Approved, Illicit, Investigational, Withdrawn
Sildenafil	The metabolism of Venlafaxine can be decreased when combined with Sildenafil.	Approved, Investigational
Silodosin	The serum concentration of Silodosin can be increased when it is combined with Venlafaxine.	Approved
Siltuximab	The serum concentration of Venlafaxine can be decreased when it is combined with Siltuximab.	Approved
Simvastatin	The metabolism of Simvastatin can be decreased when combined with Venlafaxine.	Approved
Sirolimus	The metabolism of Sirolimus can be decreased when combined with Venlafaxine.	Approved, Investigational
Sitagliptin	The metabolism of Sitagliptin can be decreased when combined with Venlafaxine.	Approved, Investigational
Sodium oxybate	The risk or severity of adverse effects can be increased when Sodium oxybate is combined with Venlafaxine.	Approved
Sofosbuvir	The serum concentration of Sofosbuvir can be increased when it is combined with Venlafaxine.	Approved
Solabegron	Venlafaxine may increase the tachycardic activities of Solabegron.	Investigational
Solifenacin	The metabolism of Solifenacin can be decreased when combined with Venlafaxine.	Approved
Sonidegib	The serum concentration of Sonidegib can be increased when it is combined with Venlafaxine.	Approved, Investigational
Sorafenib	The metabolism of Sorafenib can be decreased when combined with Venlafaxine.	Approved, Investigational
Sotalol	Venlafaxine may increase the QTc-prolonging activities of Sotalol.	Approved
Sparfloxacin	The serum concentration of Sparfloxacin can be increased when it is combined with Venlafaxine.	Approved
Sparteine	The metabolism of Sparteine can be decreased when combined with Venlafaxine.	Experimental
Sphingosine	The serum concentration of Sphingosine can be increased when it is combined with Venlafaxine.	Experimental
Spiramycin	The metabolism of Spiramycin can be decreased when combined with Venlafaxine.	Approved
Spironolactone	The serum concentration of Venlafaxine can be increased when it is combined with Spironolactone.	Approved
St. John's Wort	The serum concentration of Venlafaxine can be decreased when it is combined with St. John's Wort.	Nutraceutical
Staurosporine	The serum concentration of Venlafaxine can be increased when it is combined with Staurosporine.	Experimental
Stiripentol	The serum concentration of Venlafaxine can be increased when it is combined with Stiripentol.	Approved
Streptozocin	The serum concentration of Venlafaxine can be decreased when it is combined with Streptozocin.	Approved
Sufentanil	The metabolism of Sufentanil can be decreased when combined with Venlafaxine.	Approved, Investigational
Sulfadiazine	The metabolism of Venlafaxine can be decreased when combined with Sulfadiazine.	Approved, Vet Approved
Sulfamethoxazole	The metabolism of Sulfamethoxazole can be decreased when combined with Venlafaxine.	Approved
Sulfinpyrazone	The metabolism of Sulfinpyrazone can be decreased when combined with Venlafaxine.	Approved
Sulfisoxazole	The metabolism of Venlafaxine can be decreased when combined with Sulfisoxazole.	Approved, Vet Approved
Sulpiride	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Sulpiride.	Approved
Sultopride	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Sultopride.	Experimental
Sumatriptan	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Sumatriptan.	Approved, Investigational
Sunitinib	The metabolism of Sunitinib can be decreased when combined with Venlafaxine.	Approved, Investigational
Suvorexant	The serum concentration of Suvorexant can be increased when it is combined with Venlafaxine.	Approved
Synephrine	Venlafaxine may increase the tachycardic activities of Synephrine.	Experimental
Synthetic Conjugated Estrogens, A	The metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Venlafaxine.	Approved
Synthetic Conjugated Estrogens, B	The metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Venlafaxine.	Approved
Tacrine	The serum concentration of Venlafaxine can be increased when it is combined with Tacrine.	Withdrawn
Tacrolimus	The metabolism of Tacrolimus can be decreased when combined with Venlafaxine.	Approved, Investigational
Tadalafil	The metabolism of Tadalafil can be decreased when combined with Venlafaxine.	Approved, Investigational
Talinolol	The serum concentration of Talinolol can be increased when it is combined with Venlafaxine.	Investigational
Tamoxifen	The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Venlafaxine resulting in a loss in efficacy.	Approved
Tamsulosin	The metabolism of Tamsulosin can be decreased when combined with Venlafaxine.	Approved, Investigational
Tandospirone	The risk or severity of adverse effects can be increased when Tandospirone is combined with Venlafaxine.	Investigational
Tapentadol	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Tapentadol.	Approved
Tasimelteon	The risk or severity of adverse effects can be increased when Tasimelteon is combined with Venlafaxine.	Approved
Tasosartan	The metabolism of Tasosartan can be decreased when combined with Venlafaxine.	Approved
Taurochenodeoxycholic acid	The metabolism of Taurochenodeoxycholic acid can be decreased when combined with Venlafaxine.	Experimental
Taurocholic Acid	The serum concentration of Taurocholic Acid can be increased when it is combined with Venlafaxine.	Experimental
Technetium Tc-99m sestamibi	The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Venlafaxine.	Approved
Tedizolid Phosphate	Tedizolid Phosphate may increase the serotonergic activities of Venlafaxine.	Approved
Tegaserod	The metabolism of Tegaserod can be decreased when combined with Venlafaxine.	Investigational, Withdrawn
Telaprevir	The metabolism of Venlafaxine can be decreased when combined with Telaprevir.	Withdrawn
Telavancin	Venlafaxine may increase the QTc-prolonging activities of Telavancin.	Approved
Telithromycin	The metabolism of Venlafaxine can be decreased when combined with Telithromycin.	Approved
Telmisartan	The serum concentration of Venlafaxine can be increased when it is combined with Telmisartan.	Approved, Investigational
Temazepam	The metabolism of Temazepam can be decreased when combined with Venlafaxine.	Approved
Temsirolimus	The metabolism of Temsirolimus can be decreased when combined with Venlafaxine.	Approved
Teniposide	The metabolism of Teniposide can be decreased when combined with Venlafaxine.	Approved
Terazosin	The serum concentration of Venlafaxine can be increased when it is combined with Terazosin.	Approved
Terbinafine	The metabolism of Venlafaxine can be decreased when combined with Terbinafine.	Approved, Investigational, Vet Approved
Terbutaline	Venlafaxine may increase the tachycardic activities of Terbutaline.	Approved
Terfenadine	The metabolism of Terfenadine can be decreased when combined with Venlafaxine.	Withdrawn
Terguride	The risk or severity of adverse effects can be increased when Terguride is combined with Venlafaxine.	Experimental
Tertatolol	The serum concentration of Tertatolol can be increased when it is combined with Venlafaxine.	Experimental
Tesmilifene	The metabolism of Tesmilifene can be decreased when combined with Venlafaxine.	Investigational
Testosterone	The metabolism of Testosterone can be decreased when combined with Venlafaxine.	Approved, Investigational
Tetrabenazine	Venlafaxine may increase the QTc-prolonging activities of Tetrabenazine.	Approved
Tetracaine	The risk or severity of adverse effects can be increased when Tetracaine is combined with Venlafaxine.	Approved, Vet Approved
Tetracycline	The metabolism of Tetracycline can be decreased when combined with Venlafaxine.	Approved, Vet Approved
Tetrahydropalmatine	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Tetrahydropalmatine.	Investigational
Tetrodotoxin	The risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Venlafaxine.	Investigational
Thalidomide	The risk or severity of adverse effects can be increased when Thalidomide is combined with Venlafaxine.	Approved, Investigational, Withdrawn
Theophylline	The metabolism of Theophylline can be decreased when combined with Venlafaxine.	Approved
Thiamylal	The risk or severity of adverse effects can be increased when Thiamylal is combined with Venlafaxine.	Approved, Vet Approved
Thiopental	The risk or severity of adverse effects can be increased when Thiopental is combined with Venlafaxine.	Approved, Vet Approved
Thiopropazate	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Thiopropazate.	Experimental
Thioproperazine	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Thioproperazine.	Approved
Thioridazine	The serum concentration of Thioridazine can be increased when it is combined with Venlafaxine.	Withdrawn
Thiotepa	The metabolism of Thiotepa can be decreased when combined with Venlafaxine.	Approved
Thiothixene	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Thiothixene.	Approved
Thyroid, porcine	The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Venlafaxine.	Approved
Tiagabine	The metabolism of Tiagabine can be decreased when combined with Venlafaxine.	Approved
Tiapride	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Tiapride.	Approved, Investigational
Ticagrelor	The metabolism of Ticagrelor can be decreased when combined with Venlafaxine.	Approved
Ticlopidine	The metabolism of Venlafaxine can be decreased when combined with Ticlopidine.	Approved
Tiletamine	The risk or severity of adverse effects can be increased when Tiletamine is combined with Venlafaxine.	Vet Approved
Tilidine	Tilidine may increase the serotonergic activities of Venlafaxine.	Experimental
Timolol	The serum concentration of Timolol can be increased when it is combined with Venlafaxine.	Approved
Tinidazole	The metabolism of Tinidazole can be decreased when combined with Venlafaxine.	Approved, Investigational
Tioclomarol	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Tioclomarol.	Experimental
Tiotropium	The metabolism of Tiotropium can be decreased when combined with Venlafaxine.	Approved
Tipranavir	The metabolism of Venlafaxine can be decreased when combined with Tipranavir.	Approved, Investigational
Tizanidine	Venlafaxine may increase the tachycardic activities of Tizanidine.	Approved
Tocilizumab	The serum concentration of Venlafaxine can be decreased when it is combined with Tocilizumab.	Approved
Tofacitinib	The metabolism of Tofacitinib can be decreased when combined with Venlafaxine.	Approved, Investigational
Tolazamide	Venlafaxine may increase the hypoglycemic activities of Tolazamide.	Approved
Tolbutamide	The metabolism of Venlafaxine can be decreased when combined with Tolbutamide.	Approved
Tolcapone	The risk or severity of adverse effects can be increased when Tolcapone is combined with Venlafaxine.	Approved, Withdrawn
Toloxatone	Toloxatone may increase the serotonergic activities of Venlafaxine.	Approved
Tolterodine	The metabolism of Tolterodine can be decreased when combined with Venlafaxine.	Approved, Investigational
Tolvaptan	The serum concentration of Tolvaptan can be increased when it is combined with Venlafaxine.	Approved
Topiramate	The metabolism of Venlafaxine can be decreased when combined with Topiramate.	Approved
Topiroxostat	The metabolism of Venlafaxine can be decreased when combined with Topiroxostat.	Approved
Topotecan	The serum concentration of Topotecan can be increased when it is combined with Venlafaxine.	Approved, Investigational
Toremifene	Venlafaxine may increase the QTc-prolonging activities of Toremifene.	Approved, Investigational
Trabectedin	The serum concentration of Trabectedin can be increased when it is combined with Venlafaxine.	Approved, Investigational
Tramadol	Venlafaxine may increase the neuroexcitatory activities of Tramadol.	Approved, Investigational
Trans-2-Phenylcyclopropylamine	The risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Venlafaxine.	Experimental
Tranylcypromine	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Tranylcypromine.	Approved
Trastuzumab emtansine	The metabolism of Trastuzumab emtansine can be decreased when combined with Venlafaxine.	Approved
Trazodone	Venlafaxine may increase the serotonergic activities of Trazodone.	Approved, Investigational
Tretinoin	The metabolism of Tretinoin can be decreased when combined with Venlafaxine.	Approved, Investigational, Nutraceutical
Tretoquinol	Venlafaxine may increase the tachycardic activities of Tretoquinol.	Experimental
Triamcinolone	The metabolism of Triamcinolone can be decreased when combined with Venlafaxine.	Approved, Vet Approved
Triazolam	The metabolism of Triazolam can be decreased when combined with Venlafaxine.	Approved
Tricaine methanesulfonate	The risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Venlafaxine.	Vet Approved
Trichlormethiazide	Venlafaxine may increase the hyponatremic activities of Trichlormethiazide.	Approved, Vet Approved
Trichloroethylene	The risk or severity of adverse effects can be increased when Trichloroethylene is combined with Venlafaxine.	Experimental
Trifluoperazine	The serum concentration of Venlafaxine can be increased when it is combined with Trifluoperazine.	Approved
Trifluperidol	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Trifluperidol.	Experimental
Triflupromazine	The serum concentration of Venlafaxine can be increased when it is combined with Triflupromazine.	Approved, Vet Approved
Trimethadione	The metabolism of Trimethadione can be decreased when combined with Venlafaxine.	Approved
Trimethoprim	The metabolism of Trimethoprim can be decreased when combined with Venlafaxine.	Approved, Vet Approved
Trimipramine	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Trimipramine.	Approved
Triprolidine	The risk or severity of adverse effects can be increased when Triprolidine is combined with Venlafaxine.	Approved
Troglitazone	The metabolism of Troglitazone can be decreased when combined with Venlafaxine.	Withdrawn
Troleandomycin	The metabolism of Troleandomycin can be decreased when combined with Venlafaxine.	Approved
Tropisetron	Tropisetron may increase the serotonergic activities of Venlafaxine.	Approved, Investigational
Tulobuterol	Venlafaxine may increase the tachycardic activities of Tulobuterol.	Investigational
Ubidecarenone	The serum concentration of Ubidecarenone can be increased when it is combined with Venlafaxine.	Experimental
Udenafil	The metabolism of Udenafil can be decreased when combined with Venlafaxine.	Approved, Investigational
Ulipristal	The serum concentration of Ulipristal can be increased when it is combined with Venlafaxine.	Approved
Umeclidinium	The serum concentration of Umeclidinium can be increased when it is combined with Venlafaxine.	Approved
Valbenazine	The metabolism of Valbenazine can be decreased when combined with Venlafaxine.	Approved, Investigational
Valdecoxib	Venlafaxine may increase the antiplatelet activities of Valdecoxib.	Investigational, Withdrawn
Valproic Acid	The metabolism of Venlafaxine can be decreased when combined with Valproic Acid.	Approved, Investigational
Valsartan	The metabolism of Venlafaxine can be decreased when combined with Valsartan.	Approved, Investigational
Vandetanib	Venlafaxine may increase the QTc-prolonging activities of Vandetanib.	Approved
Vanoxerine	The metabolism of Vanoxerine can be decreased when combined with Venlafaxine.	Investigational
Vardenafil	The metabolism of Vardenafil can be decreased when combined with Venlafaxine.	Approved
Vecuronium	The serum concentration of Vecuronium can be increased when it is combined with Venlafaxine.	Approved
Velpatasvir	The metabolism of Velpatasvir can be decreased when combined with Venlafaxine.	Approved
Vemurafenib	Venlafaxine may increase the QTc-prolonging activities of Vemurafenib.	Approved
Venetoclax	The metabolism of Venetoclax can be decreased when combined with Venlafaxine.	Approved
Veralipride	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Veralipride.	Experimental
Verapamil	The metabolism of Verapamil can be decreased when combined with Venlafaxine.	Approved
Vernakalant	The metabolism of Vernakalant can be decreased when combined with Venlafaxine.	Approved, Investigational
Vicriviroc	The metabolism of Vicriviroc can be decreased when combined with Venlafaxine.	Investigational
Vigabatrin	The risk or severity of adverse effects can be increased when Vigabatrin is combined with Venlafaxine.	Approved
Vilanterol	The metabolism of Vilanterol can be decreased when combined with Venlafaxine.	Approved
Vilazodone	The serum concentration of Vilazodone can be increased when it is combined with Venlafaxine.	Approved
Vinblastine	The metabolism of Vinblastine can be decreased when combined with Venlafaxine.	Approved
Vincristine	The serum concentration of Vincristine can be increased when it is combined with Venlafaxine.	Approved, Investigational
Vincristine	The metabolism of Vincristine can be decreased when combined with Venlafaxine.	Approved, Investigational
Vindesine	The serum concentration of Vindesine can be increased when it is combined with Venlafaxine.	Approved
Vinorelbine	The metabolism of Vinorelbine can be decreased when combined with Venlafaxine.	Approved, Investigational
Vinyl ether	The risk or severity of adverse effects can be increased when Vinyl ether is combined with Venlafaxine.	Experimental
Vismodegib	The metabolism of Vismodegib can be decreased when combined with Venlafaxine.	Approved
Voriconazole	The risk or severity of adverse effects can be increased when Voriconazole is combined with Venlafaxine.	Approved, Investigational
Vortioxetine	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Vortioxetine.	Approved
Voxilaprevir	The metabolism of Voxilaprevir can be decreased when combined with Venlafaxine.	Approved
Warfarin	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Warfarin.	Approved
Xamoterol	Venlafaxine may increase the tachycardic activities of Xamoterol.	Experimental
Xenon	The risk or severity of adverse effects can be increased when Xenon is combined with Venlafaxine.	Experimental
Xylazine	Venlafaxine may increase the tachycardic activities of Xylazine.	Vet Approved
Xylometazoline	Venlafaxine may decrease the antihypertensive activities of Xylometazoline.	Approved
YM-178	Venlafaxine may increase the tachycardic activities of YM-178.	Investigational
Yohimbine	The metabolism of Yohimbine can be decreased when combined with Venlafaxine.	Approved, Vet Approved
Zafirlukast	The metabolism of Zafirlukast can be decreased when combined with Venlafaxine.	Approved, Investigational
Zalcitabine	The metabolism of Zalcitabine can be decreased when combined with Venlafaxine.	Approved
Zaleplon	The metabolism of Zaleplon can be decreased when combined with Venlafaxine.	Approved, Illicit, Investigational
Ziconotide	The risk or severity of adverse effects can be increased when Ziconotide is combined with Venlafaxine.	Approved
Zidovudine	The metabolism of Zidovudine can be decreased when combined with Venlafaxine.	Approved
Zileuton	The metabolism of Zileuton can be decreased when combined with Venlafaxine.	Approved, Investigational, Withdrawn
Zimelidine	Venlafaxine may increase the serotonergic activities of Zimelidine.	Withdrawn
Ziprasidone	Venlafaxine may increase the QTc-prolonging activities of Ziprasidone.	Approved
Zolazepam	The risk or severity of adverse effects can be increased when Zolazepam is combined with Venlafaxine.	Vet Approved
Zolmitriptan	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Zolmitriptan.	Approved, Investigational
Zolpidem	The metabolism of Zolpidem can be decreased when combined with Venlafaxine.	Approved
Zomepirac	The metabolism of Zomepirac can be decreased when combined with Venlafaxine.	Withdrawn
Zonisamide	The metabolism of Zonisamide can be decreased when combined with Venlafaxine.	Approved, Investigational
Zopiclone	The serum concentration of Zopiclone can be increased when it is combined with Venlafaxine.	Approved
Zotepine	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Zotepine.	Approved
Zucapsaicin	The metabolism of Venlafaxine can be decreased when combined with Zucapsaicin.	Approved
Zuclopenthixol	The serum concentration of Zuclopenthixol can be increased when it is combined with Venlafaxine.	Approved, Investigational

Food Interactions

Avoid alcohol.
Avoid St.John's Wort.
Take with food.

References

Synthesis Reference

Thomas P. Jerussi, Chrisantha H. Senanayake, "Derivatives of (+)-venlafaxine and methods of preparing and using the same." U.S. Patent US6197828, issued June, 1994.

US6197828

General References

Golden RN, Nicholas L: Antidepressant efficacy of venlafaxine. Depress Anxiety. 2000;12 Suppl 1:45-9. [PubMed:11098413]
Thase ME, Clayton AH, Haight BR, Thompson AH, Modell JG, Johnston JA: A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability. J Clin Psychopharmacol. 2006 Oct;26(5):482-8. [PubMed:16974189]
Bielski RJ, Ventura D, Chang CC: A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry. 2004 Sep;65(9):1190-6. [PubMed:15367045]
Rowbotham MC, Goli V, Kunz NR, Lei D: Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain. 2004 Aug;110(3):697-706. [PubMed:15288411]
Ozyalcin SN, Talu GK, Kiziltan E, Yucel B, Ertas M, Disci R: The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache. 2005 Feb;45(2):144-52. [PubMed:15705120]
Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, Altman RB, Klein TE: Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012 Oct;92(4):414-7. doi: 10.1038/clpt.2012.96. [PubMed:22992668]
Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]

External Links

Human Metabolome Database: HMDB05016
KEGG Drug: D08670
KEGG Compound: C07187
PubChem Compound: 5656
PubChem Substance: 46504593
ChemSpider: 5454
BindingDB: 82071
ChEBI: 9943
ChEMBL: CHEMBL637
Therapeutic Targets Database: DAP000054
PharmGKB: PA451866
RxList: RxList Drug Page
Drugs.com: Drugs.com Drug Page
PDRhealth: PDRhealth Drug Page
Wikipedia: Venlafaxine

ATC Codes

N06AX16 — Venlafaxine

AHFS Codes

28:16.04.16 — Selective Serotonin and Norepinephrine-reuptake Inhibitors

FDA label

Download (3.38 MB)

MSDS

Download (36.5 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Completed	Not Available	Healthy Volunteers	8
1	Completed	Basic Science	Bypass, Gastric / Post-gastrointestinal bypass surgery / Roux-en-Y Gastric Bypass	1
1	Completed	Basic Science	Healthy Volunteers	1
1	Completed	Treatment	Healthy Volunteers	2
1	Recruiting	Prevention	Alzheimer's Disease (AD)	1
1, 2	Active Not Recruiting	Treatment	Depressive State / Major Depressive Disorder (MDD)	1
1, 2	Completed	Treatment	Fibromyalgia	1
1, 2	Recruiting	Treatment	Depressive State / Major Depressive Disorder (MDD)	1
2	Active Not Recruiting	Treatment	Major Depressive Disorder (MDD)	1
2	Completed	Prevention	Cervical Pain	1
2	Completed	Treatment	Bipolar Disorder (BD) / Depressive Disorders	1
2	Completed	Treatment	Cancer, Breast	1
2	Completed	Treatment	Cocaine-Related Disorders	1
2	Completed	Treatment	Depressive Disorders	1
2	Completed	Treatment	Depressive State / Marijuana Abuse	1
2	Completed	Treatment	Generalized Anxiety Disorder (GAD)	1
2	Completed	Treatment	Major Depressive Disorder (MDD)	3
2	Completed	Treatment	Post-traumatic Neuropathic Pain	1
2	Terminated	Treatment	Anxiety Disorders	1
2	Terminated	Treatment	Depressive State	1
2	Terminated	Treatment	Major Depressive Disorder (MDD)	1
2	Terminated	Treatment	Prostate Cancer	1
2, 3	Completed	Treatment	Alcohol-Related Disorders / Anxiety Disorders	1
2, 3	Completed	Treatment	Depressive State	1
2, 3	Completed	Treatment	Depressive State / Suicide, Attempted	1
3	Completed	Prevention	Depressive State	1
3	Completed	Supportive Care	Bone Mineral Density Quantitative Trait Locus 7	1
3	Completed	Supportive Care	Menopausal Hot Flushes	1
3	Completed	Supportive Care	Menopausal Hot Flushes / Prostate Cancer	1
3	Completed	Treatment	Adenocarcinoma, Prostate	1
3	Completed	Treatment	Anxiety Disorders	2
3	Completed	Treatment	Depressive State	3
3	Completed	Treatment	Depressive State / Parkinson's Disease (PD)	1
3	Completed	Treatment	Feeling Anxious	1
3	Completed	Treatment	Healthy Volunteers	1
3	Completed	Treatment	Major Depressive Disorder (MDD)	8
3	Completed	Treatment	Major Depressive Disorder (MDD) / Sleeplessness	1
3	Completed	Treatment	Major Depressive Disorder (MDD) / Treatment Resistant Depression (TRD)	1
3	Completed	Treatment	Panic Disorders	3
3	Completed	Treatment	Social Anxiety Disorder (SAD)	1
3	Recruiting	Treatment	Anxiety Disorders / Dementias / Depressive State / Psychosomatic Disorders / Schizophrenic Disorders	1
4	Active Not Recruiting	Treatment	Obstructive Sleep Apnea (OSA)	1
4	Completed	Not Available	Depressive State	1
4	Completed	Not Available	Roux En Y Gastric Bypass / Sleeve Gastrectomy	1
4	Completed	Basic Science	Depressive State	1
4	Completed	Basic Science	Healthy Volunteers	1
4	Completed	Treatment	Anxiety Disorders	1
4	Completed	Treatment	Anxiety Disorders / Depressive State	1
4	Completed	Treatment	Back Pain / Depressive State	1
4	Completed	Treatment	Bipolar Disorder (BD)	2
4	Completed	Treatment	Bipolar Disorder (BD) / Depressive Disorders / Depressive State	1
4	Completed	Treatment	Bipolar Disorder (BD) / Depressive State	1
4	Completed	Treatment	Bipolar Type II Disorder	1
4	Completed	Treatment	Dementias / Depressive State	1
4	Completed	Treatment	Depressive State	6
4	Completed	Treatment	Depressive State / Post Traumatic Stress Disorder (PTSD)	1
4	Completed	Treatment	Dysthymic Disorder / Major Depressive Disorder (MDD) / Spinal Cord Injuries (SCI)	1
4	Completed	Treatment	Major Depressive Disorder (MDD)	8
4	Completed	Treatment	Major Depressive Disorder (MDD) / Recurrences	1
4	Completed	Treatment	Pain / Synovitis of osteoarthritis	1
4	Completed	Treatment	Social Phobia	1
4	Completed	Treatment	Traumatic Brain Injury (TBI)	1
4	Completed	Treatment	Vestibular Migraine	1
4	Recruiting	Not Available	Depressive Disorders / Lactation	1
4	Recruiting	Basic Science	Major Depressive Disorder (MDD)	1
4	Recruiting	Diagnostic	Asthma Bronchial / Asthma: [Nos] or [Attack] / Major Depressive Disorder (MDD)	1
4	Recruiting	Diagnostic	Severe Major Depression Disorder	1
4	Recruiting	Health Services Research	Major Depressive Disorder (MDD)	1
4	Recruiting	Treatment	Major Depressive Disorder (MDD) / Major Depressive Episode	1
4	Recruiting	Treatment	Treatment Resistant Major Depressive Disorder / Treatment Resistant Major Depressive Disorder Depression	1
4	Suspended	Treatment	Depressive State	1
4	Terminated	Treatment	Depressive State / Relapsing Remitting Multiple Sclerosis (RRMS)	1
4	Terminated	Treatment	Major Depressive Disorder (MDD)	1
4	Unknown Status	Not Available	Major Depressive Disorder (MDD)	1
4	Unknown Status	Treatment	Antidepressive Agents / Fluoxetine / Major Depressive Disorder (MDD) / Pharmacogenetics / Venlafaxine	1
4	Unknown Status	Treatment	Major Depressive Disorder (MDD)	2
4	Withdrawn	Treatment	Major Depressive Disorder (MDD)	1
4	Withdrawn	Treatment	Posttraumatic Stress Disorders	1
Not Available	Active Not Recruiting	Not Available	Anxiety Disorders / Generalized Anxiety Disorder (GAD) / Obsessive-Compulsive Disorder (OCD) / Panic Disorders / Post-Traumatic Stress Disorder (PTSD) / Social Anxiety Disorder (SAD)	1
Not Available	Active Not Recruiting	Not Available	Cancer, Breast / Depressive State / Menopausal Hot Flushes / Psychosocial Effects of Cancer and Its Treatment	1
Not Available	Active Not Recruiting	Not Available	Depression/Depressed State	1
Not Available	Active Not Recruiting	Not Available	Major Depressive Disorder (MDD)	1
Not Available	Active Not Recruiting	Supportive Care	Peripheral Neuropathy	1
Not Available	Active Not Recruiting	Treatment	Depressive State	1
Not Available	Completed	Not Available	Acute Kidney Injury (AKI) / Depressive State	1
Not Available	Completed	Basic Science	Major Depressive Disorder (MDD)	2
Not Available	Completed	Supportive Care	Cancer, Breast / Menopausal Hot Flushes / Sleep disorders and disturbances	1
Not Available	Completed	Treatment	Alzheimer's Disease (AD) / Depressive State	1
Not Available	Completed	Treatment	Depressive Disorders / Depressive State	1
Not Available	Completed	Treatment	Depressive Disorders / Depressive State / Major Depressive Disorder (MDD) / Unipolar Depression	1
Not Available	Completed	Treatment	Indigestion	1
Not Available	Completed	Treatment	Menopausal Hot Flushes / Menopause / Vasomotor Disturbance	1
Not Available	Completed	Treatment	Pain / Pain, Neuropathic / Spinal Cord Injuries (SCI)	1
Not Available	Completed	Treatment	Spinal Cord Injuries (SCI)	1
Not Available	Enrolling by Invitation	Not Available	Bipolar Disorder (BD)	1
Not Available	Recruiting	Treatment	Alcohol-Related Disorders / Brain Injury / Chronic Diseases / Depressive State / Mild Cognitive Impairment (MCI) / Pain / Posttraumatic Stress Disorders / Quality of Life / Substance-Related Disorders / Suicidal Ideation / Wounds and Injuries	1
Not Available	Recruiting	Treatment	Depressive State / Feeling Anxious / Mild Cognitive Impairment (MCI)	1
Not Available	Unknown Status	Not Available	Major Depressive Disorder (MDD)	1
Not Available	Unknown Status	Treatment	Major Depressive Disorder (MDD)	2
Not Available	Unknown Status	Treatment	Treatment Resistant Depression (TRD)	1
Not Available	Withdrawn	Supportive Care	Menopausal Hot Flushes	1

Pharmacoeconomics

Manufacturers

Wyeth pharmaceuticals inc
Teva pharmaceuticals usa inc
Osmotica pharmaceutical corp
Actavis totowa llc
Amneal pharmaceuticals
Aurobindo pharma ltd
Caraco pharmaceutical laboratories ltd
Dr reddys laboratories ltd
Mylan pharmaceuticals inc
Pliva hrvatska doo
Sandoz inc
Vintage pharmaceuticals llc
Zydus pharmaceuticals usa inc
Wyeth

Packagers

Advanced Pharmaceutical Services Inc.
Amerisource Health Services Corp.
AQ Pharmaceuticals Inc.
A-S Medication Solutions LLC
Bryant Ranch Prepack
Cadila Healthcare Ltd.
Caraco Pharmaceutical Labs
Cardinal Health
Caremark LLC
Direct Pharmaceuticals Inc.
Dispensing Solutions
Diversified Healthcare Services Inc.
Doctor Reddys Laboratories Ltd.
Heartland Repack Services LLC
Innoviant Pharmacy Inc.
Kaiser Foundation Hospital
Lake Erie Medical and Surgical Supply
Murfreesboro Pharmaceutical Nursing Supply
Mylan
Nucare Pharmaceuticals Inc.
Palmetto Pharmaceuticals Inc.
PD-Rx Pharmaceuticals Inc.
Physicians Total Care Inc.
Prepackage Specialists
Prepak Systems Inc.
Rebel Distributors Corp.
Remedy Repack
Resource Optimization and Innovation LLC
Schwarz Pharma Inc.
Southwood Pharmaceuticals
Stat Rx Usa
Teva Pharmaceutical Industries Ltd.
Tya Pharmaceuticals
UDL Laboratories
Upstate Pharma LLC
Vangard Labs Inc.
Wyeth Pharmaceuticals
Zydus Pharmaceuticals

Dosage forms

Form	Route	Strength
Capsule, extended release	Oral	150.0 mg
Capsule, extended release	Oral	75.0 mg
Tablet	Oral	37.5 mg
Tablet	Oral	50 mg
Tablet	Oral	75 mg
Capsule, extended release	Oral	150 mg
Capsule, extended release	Oral	150 mg/1
Capsule, extended release	Oral	37.5 mg
Capsule, extended release	Oral	37.5 mg/1
Capsule, extended release	Oral	75 mg/1
Capsule, extended release	Oral	75 mg
Tablet	Oral	37.5 mg/1
Tablet	Oral	75 mg/1
Capsule, coated, extended release	Oral	75 mg/1
Capsule, delayed release	Oral	75 mg/1
Tablet	Oral	100 mg/1
Tablet	Oral	25 mg/1
Tablet	Oral	50 mg/1
Tablet, extended release	Oral	150 mg/1
Tablet, extended release	Oral	225 mg/1
Tablet, extended release	Oral	37.5 mg/1
Tablet, extended release	Oral	75 mg/1
Tablet, film coated, extended release	Oral	150 mg/1
Tablet, film coated, extended release	Oral	225 mg/1
Tablet, film coated, extended release	Oral	37.5 mg/1
Tablet, film coated, extended release	Oral	75 mg/1

Prices

Unit description	Cost	Unit
Venlafaxine HCl 30 225 mg 24 Hour tablet Bottle	276.98USD	bottle
Effexor XR 30 37.5 mg 24 Hour Capsule Bottle	144.33USD	bottle
Venlafaxine HCl 30 37.5 mg 24 Hour tablet Bottle	114.46USD	bottle
Effexor 30 75 mg tablet Bottle	87.83USD	bottle
Effexor 30 25 mg tablet Bottle	74.82USD	bottle
Effexor XR 150 mg 24 Hour Capsule	5.87USD	capsule
Effexor xr 150 mg capsule	5.65USD	capsule
Effexor XR 75 mg 24 Hour Capsule	5.39USD	capsule
Effexor xr 75 mg capsule	4.76USD	capsule
Venlafaxine HCl 150 mg 24 Hour tablet	4.72USD	tablet
Effexor xr 37.5 mg capsule	4.63USD	capsule
Venlafaxine HCl 75 mg 24 Hour tablet	4.42USD	tablet
Effexor 100 mg tablet	2.92USD	tablet
Effexor 75 mg tablet	2.7USD	tablet
Effexor 50 mg tablet	2.6USD	tablet
Effexor 37.5 mg tablet	2.5USD	tablet
Effexor 25 mg tablet	2.4USD	tablet
Venlafaxine hcl 100 mg tablet	2.36USD	tablet
Venlafaxine hcl 75 mg tablet	2.23USD	tablet
Effexor Xr 150 mg Extended-Release Capsule	2.16USD	capsule
Venlafaxine hcl 50 mg tablet	2.1USD	tablet
Effexor Xr 75 mg Extended-Release Capsule	2.05USD	capsule
Venlafaxine hcl 37.5 mg tablet	2.04USD	tablet
Venlafaxine hcl 25 mg tablet	1.98USD	tablet
Apo-Venlafaxine Xr 150 mg Extended-Release Capsule	1.2USD	capsule
Co Venlafaxine Xr 150 mg Extended-Release Capsule	1.2USD	capsule
Mylan-Venlafaxine Xr 150 mg Extended-Release Capsule	1.2USD	capsule
Novo-Venlafaxine Xr 150 mg Extended-Release Capsule	1.2USD	capsule
Pms-Venlafaxine Xr 150 mg Extended-Release Capsule	1.2USD	capsule
Ratio-Venlafaxine Xr 150 mg Extended-Release Capsule	1.2USD	capsule
Sandoz Venlafaxine Xr 150 mg Extended-Release Capsule	1.2USD	capsule
Apo-Venlafaxine Xr 75 mg Extended-Release Capsule	1.14USD	capsule
Co Venlafaxine Xr 75 mg Extended-Release Capsule	1.14USD	capsule
Mylan-Venlafaxine Xr 75 mg Extended-Release Capsule	1.14USD	capsule
Novo-Venlafaxine Xr 75 mg Extended-Release Capsule	1.14USD	capsule
Pms-Venlafaxine Xr 75 mg Extended-Release Capsule	1.14USD	capsule
Ratio-Venlafaxine Xr 75 mg Extended-Release Capsule	1.14USD	capsule
Sandoz Venlafaxine Xr 75 mg Extended-Release Capsule	1.14USD	capsule
Effexor Xr 37.5 mg Extended-Release Capsule	1.02USD	capsule
Apo-Venlafaxine Xr 37.5 mg Extended-Release Capsule	0.57USD	capsule
Co Venlafaxine Xr 37.5 mg Extended-Release Capsule	0.57USD	capsule
Mylan-Venlafaxine Xr 37.5 mg Extended-Release Capsule	0.57USD	capsule
Novo-Venlafaxine Xr 37.5 mg Extended-Release Capsule	0.57USD	capsule
Pms-Venlafaxine Xr 37.5 mg Extended-Release Capsule	0.57USD	capsule
Ratio-Venlafaxine Xr 37.5 mg Extended-Release Capsule	0.57USD	capsule
Sandoz Venlafaxine Xr 37.5 mg Extended-Release Capsule	0.57USD	capsule

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
US5916923	No	1993-06-28	2013-06-28
CA2126305	No	2006-10-17	2014-06-20
CA2199778	No	2005-12-20	2017-03-12
US6403120	Yes	1997-09-20	2017-09-20
US6419958	Yes	1997-09-20	2017-09-20
US6274171	Yes	1997-09-20	2017-09-20

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	215-217 °C (Hydrochloride salt)	Not Available
water solubility	572 mg/ml (Hydrochloride salt)	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.23 mg/mL	ALOGPS
logP	2.69	ALOGPS
logP	2.74	ChemAxon
logS	-3.1	ALOGPS
pKa (Strongest Acidic)	14.42	ChemAxon
pKa (Strongest Basic)	8.91	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	3	ChemAxon
Hydrogen Donor Count	1	ChemAxon
Polar Surface Area	32.7 Å²	ChemAxon
Rotatable Bond Count	5	ChemAxon
Refractivity	83.02 m³·mol^-1	ChemAxon
Polarizability	32.33 Å³	ChemAxon
Number of Rings	2	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	Yes	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.9782
Blood Brain Barrier	+	0.9382
Caco-2 permeable	+	0.852
P-glycoprotein substrate	Substrate	0.6534
P-glycoprotein inhibitor I	Inhibitor	0.7031
P-glycoprotein inhibitor II	Inhibitor	0.8031
Renal organic cation transporter	Non-inhibitor	0.5792
CYP450 2C9 substrate	Non-substrate	0.7583
CYP450 2D6 substrate	Substrate	0.8919
CYP450 3A4 substrate	Substrate	0.7407
CYP450 1A2 substrate	Non-inhibitor	0.7664
CYP450 2C9 inhibitor	Non-inhibitor	0.6876
CYP450 2D6 inhibitor	Inhibitor	0.7287
CYP450 2C19 inhibitor	Non-inhibitor	0.7199
CYP450 3A4 inhibitor	Non-inhibitor	0.8308
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.8666
Ames test	Non AMES toxic	0.8
Carcinogenicity	Non-carcinogens	0.6762
Biodegradation	Not ready biodegradable	0.9941
Rat acute toxicity	2.5404 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.5486
hERG inhibition (predictor II)	Inhibitor	0.6627

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-004i-0090000000-d413fb5f16658fcc5acb
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-004i-0090000000-182f1032c3f72220679d
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-00dj-0910000000-c7a4a25a9bc95faa6db1
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-00di-0900000000-7be3d65db3af35be404e
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-00di-0900000000-615322444dcf11a7fb8d
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-03di-0090000000-d212108d9a8267ed7dad
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-004i-0090000000-0c4e12d13e69311b26bf
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0bvi-4090000000-8bf2805a95084bfd952a
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0a4i-9520000000-de599153aa118f97ad81
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0ab9-8900000000-6e9f54b654899b486e4d
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0ab9-9800000000-d762b2d7edeba1e12b28
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0ab9-9700000000-2b8ebcefcf1274550d32
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-004i-0090000000-c592b4ae2ead9b2bb7ea
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0bvi-4090000000-30b9b5dca017215ebaa4
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0a4i-9620000000-ab905f15470a13b750c5
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0ab9-8900000000-52ec7a86d35dbbd47681
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0ab9-9800000000-7a7cc5b11e1a30499063
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0ab9-9700000000-062f05f9fe2a1540985c
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-03di-0090000000-8eb971c1dc9a14696c31
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-01t9-2090000000-af607e34f7f6700231a4
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-0a4i-9140000000-0b22aeda0f56bf825768
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-0a4i-9300000000-f28ae1a2451e218836c6
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-0a4i-9400000000-c36a2f70d6d9fd69dbfe
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-0a4i-9500000000-43a71bea54c5b09c4c9a
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-0a4i-9400000000-9763935e9812b45adddb
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-0bvi-6090000000-fabb5e8a0fd59b8420ca
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-0a4i-9100000000-b67e5a7dbbd83cf2a7a7
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-0a4i-9200000000-2300decf19900a1b84e4
MS/MS Spectrum - Linear Ion Trap , positive	LC-MS/MS	splash10-03di-0090000000-40f0dac6b8ca62d0314f
MS/MS Spectrum - , positive	LC-MS/MS	splash10-01t9-0390000000-7a760936fedd0f48cebf
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-0a4i-9260000000-0b8e3be9620e0271d683
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-01t9-2090000000-94fb4781a9910b6b1932
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-0a4i-9140000000-e2c800f5f39f048c545a
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-0a4i-9400000000-e0fa4c4197355be8d0fa
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-0a4i-9500000000-23cbb70f5d3c368966bb
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-0a4i-9500000000-998e2271dd7ac0572d54
1H NMR Spectrum	1D NMR	Not Applicable
[1H,13C] 2D NMR Spectrum	2D NMR	Not Applicable

Taxonomy

Description: This compound belongs to the class of organic compounds known as anisoles. These are organic compounds containing a methoxybenzene or a derivative thereof.
Kingdom: Organic compounds
Super Class: Benzenoids
Class: Phenol ethers
Sub Class: Anisoles
Direct Parent: Anisoles
Alternative Parents: Phenoxy compounds / Methoxybenzenes / Cyclohexanols / Aralkylamines / Alkyl aryl ethers / Tertiary alcohols / 1,3-aminoalcohols / Trialkylamines / Cyclic alcohols and derivatives / Organopnictogen compoundsHydrocarbon derivatives
show 1 more
Substituents: Phenoxy compound / Anisole / Methoxybenzene / Alkyl aryl ether / Aralkylamine / Cyclohexanol / Monocyclic benzene moiety / 1,3-aminoalcohol / Tertiary alcohol / Cyclic alcohol
show 12 more
Molecular Framework: Aromatic homomonocyclic compounds
External Descriptors: tertiary alcohol, tertiary amino compound, monomethoxybenzene, cyclohexanols (CHEBI:9943)

Targets

Property	Measurement	pH	Temperature (°C)	References
IC 50 (nM)	20	N/A	N/A	21413808 / 23061607
IC 50 (nM)	27	N/A	N/A	20378347
IC 50 (nM)	30	N/A	N/A	21413808
IC 50 (nM)	31	N/A	N/A	18557608
IC 50 (nM)	35	N/A	N/A	20724153
IC 50 (nM)	7	N/A	N/A	21413808
Kd (nM)	8.9	N/A	N/A	9871604
Ki (nM)	102	N/A	N/A	9400006
Ki (nM)	145	N/A	N/A	14744476
Ki (nM)	7.5	N/A	N/A	9400006
Ki (nM)	7.8	N/A	N/A	14744476
Ki (nM)	75.9	N/A	N/A	11454918
Ki (nM)	8.9	N/A	N/A	9537821
Ki (nM)	82	N/A	N/A	11750180 / 14573386

Details1. Sodium-dependent serotonin transporter

Kind: Protein
Organism: Human
Pharmacological action: Yes
Actions: Inhibitor

General Function: Serotonin:sodium symporter activity
Specific Function: Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name: SLC6A4
Uniprot ID: P31645
Uniprot Name: Sodium-dependent serotonin transporter
Molecular Weight: 70324.165 Da

References

Chen F, Larsen MB, Sanchez C, Wiborg O: The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol. 2005 Mar;15(2):193-8. [PubMed:15695064]
Gould GG, Altamirano AV, Javors MA, Frazer A: A comparison of the chronic treatment effects of venlafaxine and other antidepressants on serotonin and norepinephrine transporters. Biol Psychiatry. 2006 Mar 1;59(5):408-14. Epub 2005 Sep 2. [PubMed:16140280]
Shang Y, Gibbs MA, Marek GJ, Stiger T, Burstein AH, Marek K, Seibyl JP, Rogers JF: Displacement of serotonin and dopamine transporters by venlafaxine extended release capsule at steady state: a [123I]2beta-carbomethoxy-3beta-(4-iodophenyl)-tropane single photon emission computed tomography imaging study. J Clin Psychopharmacol. 2007 Feb;27(1):71-5. [PubMed:17224717]
Malizia AL, Melichar JM, Brown DJ, Gunn RN, Reynolds A, Jones T, Nutt DJ: Demonstration of clomipramine and venlafaxine occupation at serotonin reuptake sites in man in vivo. J Psychopharmacol. 1997;11(3):279-81. [PubMed:9305421]
Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
Van Ameringen M, Mancini C, Patterson B, Simpson W: Pharmacotherapy for social anxiety disorder: an update. Isr J Psychiatry Relat Sci. 2009;46(1):53-61. [PubMed:19728573]
Beique J, de Montigny C, Blier P, Debonnel G: Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: I. in vivo electrophysiological studies in the rat. Neuropharmacology. 2000 Jul 24;39(10):1800-12. [PubMed:10884561]
Westenberg HG: Recent advances in understanding and treating social anxiety disorder. CNS Spectr. 2009 Feb;14(2 Suppl 3):24-33. [PubMed:19238127]
Sindrup SH, Otto M, Finnerup NB, Jensen TS: Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol. 2005 Jun;96(6):399-409. [PubMed:15910402]

Property	Measurement	pH	Temperature (°C)	References
IC 50 (nM)	149	N/A	N/A	21413808 / 23061607
IC 50 (nM)	535	N/A	N/A	18557608 / 20378347
IC 50 (nM)	581	N/A	N/A	20724153
IC 50 (nM)	61	N/A	N/A	21413808
IC 50 (nM)	754	N/A	N/A	21413808
Kd (nM)	1060	N/A	N/A	9871604
Ki (nM)	1060	N/A	N/A	9537821
Ki (nM)	1420	N/A	N/A	14744476
Ki (nM)	1644	N/A	N/A	9400006
Ki (nM)	1920	N/A	N/A	14744476
Ki (nM)	2269	N/A	N/A	9400006
Ki (nM)	2480	N/A	N/A	11750180
Ki (nM)	2483	N/A	N/A	14573386
Ki (nM)	385	N/A	N/A	18557608
Ki (nM)	6310	N/A	N/A	11454918

Details2. Sodium-dependent noradrenaline transporter

Kind: Protein
Organism: Human
Pharmacological action: Yes
Actions: Inhibitor

General Function: Norepinephrine:sodium symporter activity
Specific Function: Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name: SLC6A2
Uniprot ID: P23975
Uniprot Name: Sodium-dependent noradrenaline transporter
Molecular Weight: 69331.42 Da

References

Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, Owens MJ: Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry. 2004 Feb 1;55(3):320-2. [PubMed:14744476]
Mitchell HA, Ahern TH, Liles LC, Javors MA, Weinshenker D: The effects of norepinephrine transporter inactivation on locomotor activity in mice. Biol Psychiatry. 2006 Nov 15;60(10):1046-52. Epub 2006 Aug 7. [PubMed:16893531]
Beique JC, Lavoie N, de Montigny C, Debonnel G: Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters. Eur J Pharmacol. 1998 May 15;349(1):129-32. [PubMed:9669506]
Van Ameringen M, Mancini C, Patterson B, Simpson W: Pharmacotherapy for social anxiety disorder: an update. Isr J Psychiatry Relat Sci. 2009;46(1):53-61. [PubMed:19728573]
Beique J, de Montigny C, Blier P, Debonnel G: Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: I. in vivo electrophysiological studies in the rat. Neuropharmacology. 2000 Jul 24;39(10):1800-12. [PubMed:10884561]
Westenberg HG: Recent advances in understanding and treating social anxiety disorder. CNS Spectr. 2009 Feb;14(2 Suppl 3):24-33. [PubMed:19238127]
Sindrup SH, Otto M, Finnerup NB, Jensen TS: Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol. 2005 Jun;96(6):399-409. [PubMed:15910402]

Property	Measurement	pH	Temperature (°C)	References
IC 50 (nM)	>10000	N/A	N/A	20378347
IC 50 (nM)	19600	N/A	N/A	21413808
IC 50 (nM)	4430	N/A	N/A	21413808 / 23061607
IC 50 (nM)	6670	N/A	N/A	21413808
IC 50 (nM)	7340	N/A	N/A	20724153
Kd (nM)	9300	N/A	N/A	9871604
Ki (nM)	>10000	N/A	N/A	11454918
Ki (nM)	3070	N/A	N/A	14744476
Ki (nM)	6050	N/A	N/A	14744476
Ki (nM)	7647	N/A	N/A	11750180 / 14573386
Ki (nM)	9300	N/A	N/A	9537821

Details3. Sodium-dependent dopamine transporter

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Monoamine transmembrane transporter activity
Specific Function: Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name: SLC6A3
Uniprot ID: Q01959
Uniprot Name: Sodium-dependent dopamine transporter
Molecular Weight: 68494.255 Da

References

Dawson LA, Nguyen HQ, Geiger A: Effects of venlafaxine on extracellular concentrations of 5-HT and noradrenaline in the rat frontal cortex: augmentation via 5-HT1A receptor antagonism. Neuropharmacology. 1999 Aug;38(8):1153-63. [PubMed:10462128]
Bourin M: [Psychopharmacological profile of venlafaxine]. Encephale. 1999 Jun;25 Spec No 2:21-2; discussion 23-5. [PubMed:10434156]
Barkin RL, Fawcett J: The management challenges of chronic pain: the role of antidepressants. Am J Ther. 2000 Jan;7(1):31-47. [PubMed:11319571]
Lemke MR: [Antidepressant effects of dopamine agonists. Experimental and clinical findings]. Nervenarzt. 2007 Jan;78(1):31-8. [PubMed:17187269]

Enzymes

Details1. Cytochrome P450 2D6

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate
Inhibitor

General Function: Steroid hydroxylase activity
Specific Function: Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name: CYP2D6
Uniprot ID: P10635
Uniprot Name: Cytochrome P450 2D6
Molecular Weight: 55768.94 Da

References

Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Fogelman SM, Schmider J, Venkatakrishnan K, von Moltke LL, Harmatz JS, Shader RI, Greenblatt DJ: O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology. 1999 May;20(5):480-90. [PubMed:10192828]
Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Details2. Cytochrome P450 3A4

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate
Inhibitor

General Function: Vitamin d3 25-hydroxylase activity
Specific Function: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name: CYP3A4
Uniprot ID: P08684
Uniprot Name: Cytochrome P450 3A4
Molecular Weight: 57342.67 Da

References

Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Details3. Cytochrome P450 2C9

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate

General Function: Steroid hydroxylase activity
Specific Function: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name: CYP2C9
Uniprot ID: P11712
Uniprot Name: Cytochrome P450 2C9
Molecular Weight: 55627.365 Da

References

Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Details4. Cytochrome P450 2C19

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate

General Function: Steroid hydroxylase activity
Specific Function: Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name: CYP2C19
Uniprot ID: P33261
Uniprot Name: Cytochrome P450 2C19
Molecular Weight: 55930.545 Da

References

Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Details5. Cytochrome P450 2B6

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Steroid hydroxylase activity
Specific Function: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name: CYP2B6
Uniprot ID: P20813
Uniprot Name: Cytochrome P450 2B6
Molecular Weight: 56277.81 Da

References

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Details1. Multidrug resistance protein 1

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate
Inhibitor

General Function: Xenobiotic-transporting atpase activity
Specific Function: Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name: ABCB1
Uniprot ID: P08183
Uniprot Name: Multidrug resistance protein 1
Molecular Weight: 141477.255 Da

References

Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE: Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther. 2003 Apr;305(1):197-204. [PubMed:12649369]
Uhr M, Grauer MT, Holsboer F: Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol Psychiatry. 2003 Oct 15;54(8):840-6. [PubMed:14550684]
Karlsson L, Schmitt U, Josefsson M, Carlsson B, Ahlner J, Bengtsson F, Kugelberg FC, Hiemke C: Blood-brain barrier penetration of the enantiomers of venlafaxine and its metabolites in mice lacking P-glycoprotein. Eur Neuropsychopharmacol. 2010 Sep;20(9):632-40. doi: 10.1016/j.euroneuro.2010.04.004. Epub 2010 May 13. [PubMed:20466523]

Details2. ATP-binding cassette sub-family G member 2

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Inducer

General Function: Xenobiotic-transporting atpase activity
Specific Function: High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name: ABCG2
Uniprot ID: Q9UNQ0
Uniprot Name: ATP-binding cassette sub-family G member 2
Molecular Weight: 72313.47 Da

References

Bachmeier CJ, Beaulieu-Abdelahad D, Ganey NJ, Mullan MJ, Levin GM: Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine. Biopharm Drug Dispos. 2011 May;32(4):233-44. doi: 10.1002/bdd.753. Epub 2011 Mar 28. [PubMed:21446053]

Drug created on June 13, 2005 07:24 / Updated on October 21, 2017 19:21

Venlafaxine

Identification

Structure for DB00285 (Venlafaxine)

Pharmacology

Reactions:

Interactions

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Taxonomy

Targets

References

References

References

Enzymes

References

References

References

References

References

Transporters

References

References